Deubiquitination : does the answer to cardiotoxicity lie within the ubiquitin proteasome pathway by Ogundipe, Temitope R.
i 
DEUBIQUITINATION: DOES THE ANSWER TO 
CARDIOTOXICITY LIE WITHIN THE UBIQUITIN 
PROTEASOME PATHWAY? 
by  
Temitope R. Ogundipe 
Thesis presented in fulfillment of the requirements for the degree of 
Master of Science (Physiological Sciences) at Stellenbosch University 
Supervisor: Dr. Balindiwe JN Sishi 
March 2017 
ii 
DECLARATION 
By submitting this thesis electronically, I declare that the entirety of the work 
contained therein is my own, original work, that I am the sole author thereof (save to 
the extent explicitly otherwise stated), that reproduction and publication thereof by 
Stellenbosch University will not infringe any third party rights and that I have not 
previously in its entirety or in part submitted it for obtaining any qualification. 
Copyright © 2017 Stellenbosch University
All rights reserved
March 2017
Stellenbosch University  https://scholar.sun.ac.za
iii 
ABSTRACT 
Introduction: Cardiotoxicity, a complication that arises from anthracycline use is one 
that has confounded scientists for decades. Attempts have been made to attenuate 
the development of this condition through the use of anti-oxidants with little success 
and this has led to calls for new adjuvant therapies. One area that has been 
identified as a potential intervention involves the ubiquitin proteasome system (UPS) 
and its regulation and degradation of proteins that control mitochondrial morphology, 
apoptosis and cellular anti-oxidants. This process can be reversed through the use 
of de-ubiquitinating enzymes (DUBs); however their role in this context is relatively 
unknown. Therefore, this study aimed to investigate the role of specific DUBs 
relevant in this context and whether the manipulation of their protein expression 
levels will be beneficial.
Methods: Chronic doxorubicin (DOX)-induced toxicity was induced in H9C2 
cardiomyoblasts and male Sprague-Dawley rats for 120 hrs (0.2 µM) and eight 
weeks (2.5 mg/kg/week) respectively. Baseline protein expression of DUBs as well 
as their down-stream factors was determined by western blotting on both models. 
Immunocytochemistry was undertaken only for in vitro studies. DUBs were down-
regulated using SiRNA, and the subsequent effect on downstream proteins was 
determined through western blotting. Mitochondrial morphology was evaluated by 
fluorescence microscopy, while cellular toxicity and ATP production were assessed 
using a mitochondrial toxicity assay.  
Results and Discussion: DOX increased the expression of USP9x (103.7 ± 4.7%, 
p<0.01), which regulates MCL1 (long-fragment), an anti-apoptotic protein which was 
down-regulated in this scenario. Interestingly, the pro-apoptotic short-fragment of 
MCL1 was up-regulated, suggesting a mechanism by which DOX uses USP9x to 
promote apoptosis. DOX treatment also reduced USP30 expression (27.5 ± 3.7%, 
p<0.01), as well as its downstream target, the mitofusin proteins (22.7 ± 5.9%, 
p<0.001) which regulate mitochondrial fusion during mitochondrial dynamics. USP36 
showed little variation between the two groups however, DOX reduced SOD2 
expression (250.9 ± 6.8%, p<0.001). While both models utilised produced similar 
results, there was minor variation in the results. When DUB (SiRNA) was initiated in 
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the presence of DOX, mitochondrial morphology appeared to improve. Interestingly, 
while the known-down of some DUBs (USP30 and USP36) did not modify 
mitochondrial toxicity except when USP9x was abolished, ATP synthesis was 
significantly upregulated in all intervention groups when compared to DOX treatment 
alone. Although more research into this topic is urgently needed, it is clear from the 
positive results obtained above that de-ubiquitination may be a mechanism that can 
be exploited as a potential treatment strategy in this context.  
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OPSOMMING 
 
Inleiding: Kardiotoksisiteit, as gevolg van antrasiklien gebruik, is ‘n komplikasie wat 
wetenskaplikes vir dekades verwar.  Antioksidante is gebruik om die ontwikkelling 
van die toestand te probeer onderdruk, maar pogings was onsuksesvol en het 
aanleiding daartoe gegee dat nuwe ondersteuningsterapiëe ontwikkel moes word.  
Een area wat geteiken is vir potensiële intervensies sluit die 
ubikwitienproteosoomsisteem (UPS) in, en die regulering en degradering van 
proteïene wat mitochondriale morfologie, aptoptose en sellulêre antioksidante 
beheer. Hierdie proses is omkeerbaar deur die gebruik van die de-
ubikwitieneringsensiem (DUBs), maar die rol in hierdie konteks is onduidelik.  
Gevolglik het hierdie studie daarin gepoog om die rol van spesifieke DUBs wat in 
hierdie konteks verwant is, asook of die manipulering van die 
proteïenuitdrukkingsvlakke voordelig sal wees te ondersoek. 
Metodes: H9C2 kardiomioblaste en manlike Sprague-Dawley rotte is onderskeidelik 
aan 120 uur (0.2 µM) en agt weke (2.5 mg/kg/week) van chroniese doksorubisien 
(DOX)-geïnduseerde toksisiteit blootgestel. Basislyn DUBs proteïenuitdrukking, 
asook hulle afstroomfaktore is deur middel van Westerse blattering op beide 
modelle, en slegs met behulp van immunositochemie in vitro bepaal. DUBs is 
afgereguleer deur van SiRNA gebruik te maak, waarna die gevolglike effekte van die 
afstroomproteïene deur middel van Westerse blattering bepaal is.  Mitochondriale 
morfologie is deur middel van fluoresensie mikroskopie ondersoek, terwyl sellulêre 
toksisiteit en ATP produksie deur middel van ‘n mitochondriale toksisiteittoets bepaal 
is.   
Resultate en Bespreking: DOX het die uitdrukking van USP9x (103.7 ± 4.7%, 
p<0.01) verhoog wat MCL1 (langfragment) reguleer.  Laasgenoemde is ‘n anti-
apoptotiese proteïen wat afgereguleer is in hierdie scenario. Die pro-apoptotiese 
kortfragment van MCL1 was merkwaardig opgereguleer, wat moontlik ‘n meganisme 
kan beskryf waarin DOX, USP9x gebruik om apoptose te stimuleer. DOX 
behandeling het ook USP30 uitdrukking verlaag (27.5 ± 3.7%, p<0.01), asook die 
afstroomteiken, mitofusienproteïene (22.7 ± 5.9%, p<0.001) wat mitochondriale fusie 
tydens mitochondriale dinamika reguleer.  Hoewel USP36 min variasie tussen die 
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twee groepe getoon het, het DOX SOD2 uitdrukking verlaag (250.9 ± 6.8%, 
p<0.001). Beide modelle het soorgelyke resultate opgelewer, maar daar was min 
variasie in die resultate.  Nadat DUB (SiRNA) in die teenwoordigheid van DOX 
geïnisieer is, blyk dit dat die mitochondriale morfologie verbeter het.  Terwyl die 
onderdrukking van sommige DUBs (USP30 en USP36) nie die mitochondriale 
toksisiteit kon modifiseer nie, behalwe as USP9x afgeskakel was, was ATP sintese 
interresant genoeg betekenisvol opgereguleer in alle intervensie groepe in 
vergelyking met die DOX alleen groep.  Alhoewel daar nog baie navorsing gedoen 
moet word op hierdie onderwerp, is dit duidelik uit hierdie positiewe resultate dat die 
de-ubikwitienasie moontlik as megansime ondersoek kan word vir die potensiële 
behandelingsstrategie in hierdie konteks.   
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DUB De-ubquitinating enzyme 
EPI Epirubicin 
ER Endoplasmic Reticulum 
HF Heart Failure 
IDA Idarubicin 
JAB1 Jun activating binding protein 
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MFN2 Mitofusin 2 
MFNs Mitofusins 
MJD Machado-joseph domain 
MPN Mpr1/Pad1 N-terminal 
mPTP Mitochondrial permeability transition pore 
MTS Mitochondrial targeting sequence 
MnSOD Manganese superoxide dismutase 
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MULE MCL-1 ubiquitin ligase 
NRF Nuclear respiratory factor 
NTF Nuclear transcription factors 
OPA1 Optic atrophic protein 1 
OUT Ovarian-tumour domain 
OXPHOS Oxidative phosphorylation 
PBS Phosphate buffered saline 
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activator 1 alpha 
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SDS-PAGE 
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TIM/TIMM Translocase of inner mitochondrial membrane 
TOM/TOMM Translocase of outer mitochondrial membrane 
TS Transmembrane segment 
UCHs Ubiquitin c-terminal hydrolases 
UPS Ubiquitin proteasome system 
USP Ubiquitin specific protease 
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UNITS 
g gram 
mg milligram 
kg kilogram 
mM millimolar 
µM micromolar 
nM nanomolar 
M molar 
nm nanometer 
L litre 
mL millilitre 
µL microliter 
g/mL gram per milliliter 
mg/mL milligram per milliliter 
ng/mL nanogram per milliliter 
mg/m2 milligram per metre squared 
mg/kg milligrams per kilogram 
µg/kg microgram per kilogram 
o C degrees celsius 
%  percentage 
Hrs hours 
Mins minutes 
Secs seconds 
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 LITERATURE REVIEW 
1.1  Introduction 
Cardiovascular diseases (CVDs) and cancer as identified, are the two leading 
causes of death in the industrialised world and the two diseases are closely linked 
(Siegal et al., 2015). On the one hand, CVDs are a clinically complex syndrome with 
a number of causes. According to the American Heart Association (Mozaffarian et 
al., 2015), CVDs are considered the number one cause of death world-wide, 
accounting for 17.3 million deaths. This number is predicted to grow to over 23.6 
million by the year 2030. On the other hand, cancer is a major global health concern, 
second to CVDs in terms of prevalence and mortality. Together, these diseases 
accounted for 46.5% of all global deaths in 2012, where 48.5% were male and 
44.4% were female (Heron, 2015). In the African context, the picture is slightly 
different as CVDs and cancers are not the major contributors of death in the adult 
population but still pose a major burden particularly in Sub-Saharan Africa. Although 
this region is riddled with communicable diseases such as tuberculosis (TB), 
HIV/AIDS and malaria (Murray et al., 2014), over 80% of the global mortality rates 
related to CVDs currently occur in developing countries (Perk et al., 2012). Despite 
aggressive treatments and advanced diagnostic techniques, these diseases lead to 
substantial morbidity and mortality and will continue to increase in many parts of the 
world (Fig. 1.1) and therefore their prevention is a very important clinical and public 
health priority. These diseases are not only costly to manage, they have the ability to 
be highly disabling and in some cases lethal. Due to this, there is a need for novel 
adjuvant therapies that function differently to those currently established.  
The advances in cancer treatment have brought hope to patients with this disease 
which was long thought to be incurable. This has led to a significant reduction in 
mortality rates particularly amongst women who suffer from breast cancer where 
survival rates are as high as 85-90%; a major accomplishment in today’s cancer 
treatment strategies (Ginsburg, 2013). Chemotherapy is essential in cancer therapy; 
however an overwhelming body of evidence has established that patients exposed to 
different types of anti-neoplastic treatments have numerous laboratory and clinical 
indices of cardiovascular dysfunction that become progressively evident as the 
patients live longer (Broder et al., 2008). Apart from the growth and ageing of the 
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population, the increased adoption of cancer-associated lifestyle behaviours such as 
physical inactivity, westernized diets and smoking, contribute to the severity of this 
health burden (Mozaffarian et al., 2015). As a result of this phenomenon, cancer 
patients who have or are at risk of cardiovascular complications are now being 
treated collaboratively by oncologists, cardiologists, haematologists and radiologists 
in an initiative that has led to the development of an exciting but novel 
interdisciplinary field known as Cardio-Oncology (Albini et al., 2010; Patane, 2014). 
 
 
Figure 0.1: CVD and Cancer Mortality per Economic Region. CVD mortality is projected to 
increase in many parts of the world, with the largest increases projected for middle income and 
developing regions. Cancer mortality is also on the rise in middle income and low income regions. 
Abbreviations: HIV - Human immune deficiency virus, TB – Tuberculosis (Laslett et al., 2012). 
 
1.2  Cardiotoxicity 
Cardiotoxicity was initially defined by the National Cancer Institute in very general 
terms as “toxicity that affects the heart” (NCI dictionary of cancer terms: 
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www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44004; April 6, 2016). 
While this definition is somewhat acceptable, it is considered incomplete and lacks 
specificity. Some have defined this condition as a multi-factorial process that in the 
long run induces cardiomyocyte death as the terminal downstream event (Minotti et 
al., 2004), while others describe it as a broad range of adverse effects on heart 
function induced by therapeutic molecules (Montaigne et al., 2012). Although these 
definitions are to some extent better than the previous, they are still very vague since 
it is well known that various chemotherapeutic agents are toxic to the heart and its 
vasculature (Albini et al., 2010). Therefore an unambiguous interpretation of exactly 
what cardiotoxicity is, is still lacking. A more comprehensive and expansive definition 
was then postulated by the Cardiac Review and Evaluation Committee and they 
defined cardiotoxicity induced by anti-cancer treatment regimens as including one or 
more of the following:  
(i). Cardiomyopathy with a reduction in left ventricular ejection fraction 
(LVEF), either globally or more severely in the septum or, 
(ii). Symptoms associated with heart failure (HF) such as S3 gallop, 
tachycardia or both or, 
(iii). A reduction in LVEF that is less than or equal to 5% or less than 55% with 
accompanying signs or symptoms of HF or,  
(iv). A reduction in LVEF that is greater or equal to 10% or less than 55%, 
without accompanying signs or symptoms (Seidman et al., 2002). 
Whereas this definition describes cardiotoxicity in terms of HF characteristics, it is 
currently the most appropriate considering that cardiotoxicity induced by 
anthracycline treatment (discussed below) culminates in congestive heart failure 
(CHF) (Swain et al., 2003). Despite the fact that cardiotoxicity is mainly induced by 
chemotherapeutic treatments, it can also be induced from complications of anorexia 
nervosa as well as incorrectly administered drugs (Lask et al., 1997). Classic 
chemotherapy-induced cardiotoxicity is generally classified into two main types: 
early/acute and late/chronic cardiotoxicity (Minotti et al., 2004). 
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1.2.1  Early/Acute cardiotoxicity 
The more infrequent form of early/acute cardiotoxicity occurs anytime from the 
initiation of chemotherapy up to approximately two weeks after termination of 
treatment (Simunek et al., 2009). Symptoms observed in patients experiencing this 
type of cardiotoxicity include hypotension, vasodilation, transient cardiac rhythm 
disturbances, pericarditis, and left ventricular dysfunction (Volkova & Russell, 2011). 
Although improvements in left ventricular dysfunction have previously been 
observed, the mechanism that is postulated to be responsible for acute cardiotoxicity 
may potentially involve an inflammatory response, which is in contrast to the 
commonly accepted cause of the chronic form of cardiotoxicity (Bristow et al., 1978). 
Acute cardiotoxicity is also described as Type II cardiotoxicity as it is induced by 
cardiomyocyte dysfunction rather than cell death and is thus considered to be 
reversible. Typically a rare complication, early/acute cardiotoxicity is generally not 
considered a clinical cause of concern as it can either be clinically treated, or it can 
resolve on its own without intervention once chemotherapy has ceased (Simunek et 
al., 2009).  
 
1.2.2  Late/Chronic Cardiotoxicity 
Late/chronic cardiotoxicity, also known as Type I cardiotoxicity, is more serious 
taking into account that it is governed by cell death, either through apoptosis or 
necrosis. Cardiomyocyte death results in permanent damage to the myocardium and 
therefore is deemed irreversible. This progressive toxicity traditionally takes place 
following the completion of treatment and may manifest within a year (early onset) or 
many years to decades (late onset) after chemotherapy has been completed (Shan 
et al., 1996). Early onset chronic cardiotoxicity is characterized by dilated 
cardiomyopathy which eventually leads to left ventricular contractile dysfunction and 
culminates in CHF, while late onset chronic cardiotoxicity is characterized by 
asymptomatic systolic and/or diastolic left ventricular dysfunction that can lead to 
severe congestive cardiomyopathy and eventual death of the individual (Simunek et 
al., 2009). This type of cardiotoxicity is particularly relevant in adult survivors of 
childhood cancers as up to 65% of these patients display echocardiographic 
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indications of left ventricular contractile abnormalities (Grenier & Lipshultz, 1998; 
Choi et al., 2010). The risk for such toxicity depends on the cumulative dose, the rate 
of drug administration, mediastinal radiation, age, gender, hypertension and pre-
existing heart disease (Volkova & Russell. 2011). While the chemotherapeutic drugs 
often associated with cardiotoxicity include alkylating agents (e.g. Cisplatin, 
Cyclophosphamide) and monoclonal antibodies (e.g. Bevacizumab, Cetuximab), the 
most problematic of these are the anthracyclines (e.g. Doxorubicin, Daunorubicin) 
(Table 1). 
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Table 1: Available anti-neoplastic treatments and their associated side-effects. Most anti-
neoplastic drugs have some sort of side-effect, negating the option of just avoiding DOX, seen here 
are several available anti-neoplastic treatments and the side effects associated with them. +++: > 
10%, ++: 1-10%, +: 1% or rare, √: observed, but precise incidence not well established, −: not well 
recognized complication with no/minimal data. Abbreviations: CML - Chronic myeloid leukaemia, 
GIST - Gastrointestinal stromal tumour, HCC - hepatocellular carcinoma, HNC - Head and neck 
cancer, RCC - Renal cell carcinoma, TKI - Tyrosine kinase inhibitor (Truong et al., 2014). 
 
1.3  Anthracyclines 
 
Anthracyclines are a family of drugs initially discovered in the 1950s from the 
identification and isolation of β-rhodomycin II from the bacterium Streptomyces 
peucetius. This discovery led to the eventual identification of Daunorubicin (DNR) in 
the 1960s (Lown, 1993; Minotti et al., 2004). DNR was established to be quite 
successful in treating cancers of the immune system (lymphomas) and of the blood 
(leukaemia) (Tan et al., 1967). Within a decade, derivatives of DNR such as 
Doxorubicin (DOX), also known as Adriamycin (ADR), Epirubicin (EPI) and 
Idarubicin (IDA) (Fig. 1.2) were developed (Lown, 1993). While DOX is considered 
the one of the most effective and most potent anti-tumour drugs ever developed, 
DNR, EPI and IDA are considered effective, but less potent than DOX.  
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Figure 0.2: The evolution of anthracyclines. Chemical structures of four of the most common 
anthracyclines and their minor structural differences. Whereas DOX and IDA were developed from 
DNR, EPI was developed from DOX. Green circles (O) indicate differences between DNR and IDA, 
red circles (O) indicate differences between DNR and DOX and, blue circles (O) indicate differences 
between DOX and EPI. Abbreviations: DNR - Daunorubicin, DOX - Doxorubicin, EPI - Epirubicin, IDA 
– Idarubicin (Minotti, et al., 2004). 
 
Since the late 1990s, anthracyclines, and in particular DOX have been considered 
the gold standard of chemotherapy in treating a wide variety of solid tumours and 
hematologic malignancies (Volkova & Russell, 2011). Soon after their discovery, it 
was observed that their clinical utility was limited by their cumulative, dose 
dependent myocardial injury which led to irreversible HF and a reduced quality of life 
(Lown, 1993). This phenomenon has since been known as anthracycline-induced 
cardiotoxicity. In a retrospective study conducted by Van Hoff and colleagues (1979) 
of over 4000 patients receiving DOX treatment, 2.2% of these patients displayed 
signs and symptoms of CHF. While this percentage may appear to be small, this 
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number could possibly have been higher had the authors included reductions in left 
ventricular function without obvious signs and symptoms of CHF. It was further 
demonstrated that the independent risk factor for the development of CHF was the 
cumulative dose of DOX, where the incidence of HF increases with each subsequent 
dose received (Fig 1.3). It was only in 2003 when Swain et al., demonstrated that 
cumulative doses that range between 275-399 mg/m2 resulted in a decrease in 
LVEF in 4% of the patients treated with DOX. This number increased to 15% and 
28% when the cumulative doses were between 400 and 500 mg/m2, and greater 
than 500 mg/m2 respectively. As a result, the recommended lifetime cumulative dose 
for DOX that should not be exceeded is ± 450 mg/m2 (versus 900 mg/m2 for 
Epirubicin) as cardiotoxicity limits further therapy (Torti et al., 1986).  
 
Figure 0.3: Cumulative dose related risk of CHF across different age groups.  Percentage risk of 
developing HF rose with increases in the cumulative dose of DOX as shown above. This increase 
was also more evident in ageing populations. (Barrette-Lee et al., 2009) 
 
Although substantial efforts have been made in the current clinical setting to identify 
patients that display signs of cardiotoxicity based on the aforementioned risk factors; 
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the current detection methods are not sensitive enough to distinguish early signs of 
damage prior to left ventricular dysfunction (Volkova & Russell, 2011). Furthermore, 
despite the fact that clinical evaluation can identify patients at risk, there is currently 
no consensus on the optimal strategy to delay or prevent the onset of cancer-
associated heart disease. The ideal cardioprotective approach within this context 
remains controversial and thus represents an unmet clinical requirement. 
Notwithstanding that over 50 years of intense research in this field has already been 
spent, the lack of acceptable guidelines for the management of this critical 
complication predominantly originates from the limited understanding of the 
molecular mechanisms that govern cardiotoxicity and its transition to HF. An 
important question that arises from this is whether the mechanisms by which DOX 
kills actively replicating cancer cells are also the same mechanisms by which it 
induces cardiac toxicity? From this point onwards, the anthracycline that will be 
referred to in the rest of this thesis is DOX. 
 
1.3.1  Doxorubicin’s mechanism of action 
DOX is known to possess a Quinone moiety connected to a glycoside group (Fig. 
1.4). Its chemical structure is not only responsible for its anti-neoplastic activity but 
also for its toxicity. More specifically, the inhibition of DNA synthesis through DNA 
intercalation causing DNA strand breaks and ultimately apoptosis, is the primary 
mechanism by which DOX exerts its cytostatic effects on neoplastic cells (Gewirtz, 
1999); whereas the toxicity exhibited in cardiomyocytes is related to free radical 
production stimulated by DOX metabolism (Minotti et al., 2004). Firstly, NADH 
dehydrogenases reversibly reduce DOX at complex I of the mitochondrial respiratory 
chain forming a semi-Quinone radical (an unstable metabolite) that reacts with 
oxygen to produce superoxide radicals. In a vicious cycle, the continuous redox 
cycling also produces hydrogen peroxide and hydroxyl radicals, and thus a condition 
of oxidative stress arises (Bachur et al., 1978). Secondly, iron is a vital cofactor in 
the formation of toxic reactive oxygen species (ROS). The iron-catalysed conversion 
of hydrogen peroxide to hydroxyl radicals (Fenton reaction) occurs as a result of the 
formation of DOX-iron complexes (Minotti et al., 1999). Due to their high reliance on 
oxidative phosphorylation and reasonably inferior anti-oxidant defences, (Olsen et 
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al., 1981; Doroshow et al., 1980), cardiomyocytes are likely to be more sensitive to 
oxidative stress and thus prone to oxidative damage.  
 
Figure 0.4: Functional structure of DOX. DOX possess four Quinone moieties (circled in red) 
connected to a glycosidic group (circled in green) (Minotti et al., 2004). 
 
The importance of this oxidative stress theory was demonstrated by the observation 
that reducing ROS and consequently oxidative stress, ameliorates the cardiotoxic 
effects associated with DOX treatment, including cell death. Elegant studies utilizing 
transgenic models have demonstrated that the over-expression of anti-oxidants such 
as MnSOD (Su et al., 2014) and catalase (Kang et al., 1996) improves left ventricular 
function and reduces apoptosis in DOX treated animals. Others have shown that a 
decline in left ventricular function can be prevented by deleting proteins such as nitric 
oxide synthase that initiate free radical production (Vasquez-Vivar et al., 1997). 
Furthermore, DOX has a high affinity for cardiolipin, a crucial phospholipid located in 
the inner mitochondrial membrane. This binding disrupts the association that 
cardiolipin has with other inner mitochondrial membrane proteins and this affects 
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mitochondrial membrane potential and enhances cytochrome c release in response 
to oxidative stress (Goormaghtigh et al., 1980).  
Life and death signals within cardiomyocytes are a delicate balance between 
cytoprotective and cytotoxic pathways, and understanding the relationship between 
these two mechanisms may provide insight into novel treatments that may reduce 
toxicity without affecting the neoplastic activity of DOX. In this regard, a number of 
approaches have been taken in an attempt to ameliorate the toxic effects of DOX, 
one being the use of anti-oxidants to combat oxidative stress and its downstream 
effects. Van Dalen et al., (2005) observed that the use of various anti-oxidants such 
as vitamins E and C, and N-acetylcysteine (NAC), have all shown promise in vitro 
and in vivo in reducing oxidative stress, however these interventions produced 
disappointing results clinically. In fact, these patients went on to develop HF, with 
D’Andrea, (2005) going as far as to recommend the avoidance of anti-oxidants 
during chemotherapy, as their limited beneficial effects are compromised by the fact 
that they could also protect cancer cells from chemotherapy. Another intervention 
that has had more success than anti-oxidants is the iron chelating agent 
Dexrazoxane (DEX). This iron-chelator has been identified as particularly effective in 
reducing early myocardial injury during chemotherapeutic treatment with DOX 
(Lipshultz et al., 2010). DEX becomes hydrolysed to its metabolites and its potent 
iron-chelating form ADR-925 by dihydroorotase (Fig. 1.5). ADR-925 binds free iron 
released from ferritin and iron bound to DOX in DOX-iron complexes, and thereby 
prevents ROS formation through the Fenton and Haber-Weiss reactions.  
DEX also offers protection against DOX-induced cardiotoxicity via the inhibition of 
topoisomerase II expressed in high concentrations, such as in cancer cells. 
Interestingly, the inhibition of topoisomerase II is the same mechanism by which 
DOX induces cytotoxicity in cancer cells. However, it has been speculated that DEX 
may protect cancer cells by reducing the anti-tumour activity of DOX, and thus may 
play an active role in the development of secondary malignant neoplasms (Choi et 
al., 2010; Lipshultz et al., 2010). Furthermore, DEX may also increase the incidence 
of side-effects such as infection, fever and myelosuppression (Langer, 2007). Since 
the above interventions have failed to achieve desirable results clinically, the focus of 
research has shifted from oxidative stress to rather the cellular organelles that 
produce ROS. These ROS producing organelles known as mitochondria are central 
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to cardiotoxicity, considering that damaged mitochondria are one of the earliest and 
most prominent histomorphological features of DOX cardiotoxicity.  
 
Figure 0.5: Conversion of DEX to ADR-925. In a reaction catalysed by dihydroorotase, 
Dexrazoxane is converted to the potent iron-chelating agent ADR-925 (Junjing et al., 2010). 
 
1.4 Mitochondria 
 
Mitochondria are aptly named after two forms in which they represent their networks; 
‘mitos’ meaning thread, is indicative of fusion and ‘chondros’ meaning grain and 
indicates fission (Hom & Sheu, 2009). These powerhouses fulfil the high energy 
demands of the heart due to their ability to produce ATP through oxidative 
phosphorylation (Martinou & Youle, 2011). As a result, cardiomyocytes have a dense 
population of mitochondria, accounting for 35% of the myocardial volume (Hom & 
Sheu, 2009). However, as much as these organelles are crucial for cellular function 
and ATP production, they are also known for their role as the main producers of 
ROS (Daosukho et al., 2005). 
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1.4.1  Mitochondrial Dynamics 
Mitochondrial integrity is vital in governing cellular homeostasis. It is influenced by 
mitochondrial morphology which is controlled by two processes known as 
mitochondrial fusion and fission (Fig. 1.6) in an overarching process known as 
mitochondrial dynamics (Hom & Sheu, 2009). These processes contribute to overall 
cellular health as mitochondrial fission is essential for cell cycle regulation and cell 
division through the isolation and removal of polarised or damaged mitochondria. 
This event is characterised by highly fragmented and disconnected mitochondria that 
produce excessive ROS, and is often accompanied by mitophagy, a degradative 
system for damaged mitochondria (Kim et al., 2007). Mitochondrial fusion also 
contributes to mitochondrial network homeostasis by ‘diluting’ damaged 
mitochondrial regions through fusion with healthy mitochondria (Youle et al., 2012). 
Characterized by elongated, tubular and interconnected mitochondrial networks (Fig. 
1.7), fusion enables mitochondria to squeeze out as much efficiency as possible by 
keeping the network intact during damaging insults.  
 
Figure 0.6: Mitochondrial Biogenesis. PGC-1α associates with NTFs, which lead to the 
transcription of Tfam a protein which induces transcription and replication of the mitochondrial 
genome. Mitochondrial fusion is enabled by the mitofusins, while mitochondrial fission is enabled by 
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DRP1. Abbreviations: DRP1 - Dynamin related protein 1, MFN: mitofusin, NTF- Nuclear transcription 
factor, OPA1: Optic atrophic protein 1, OXPHOS: Oxidative phosphorylation, PGC-1α - Peroxisome 
proliferator-activated receptor gamma co-activator 1α, Tfam - mitochondrial transcription factor, TIM: 
Translocase of inner membrane, TOM: Translocase of outer membrane, (Ventura-Clapier et al., 
2008). 
 
Mitochondrial fusion is regulated by dynamin related GTPases mitofusin 1 (MFN1) 
and mitofusin 2 (MFN2), and the optic atrophic protein (OPA1). The mitofusins 
facilitate fusion of the outer mitochondrial membrane while OPA1 undergoes splicing 
into a long and short subunit. The long subunit (L-OPA1) merges and becomes part 
of the inner mitochondrial membrane, while the short subunit (S-OPA1) remains in 
the inner mitochondrial membrane space. These proteins are essential for 
mitochondrial stability and a loss of MFN2 alone has been shown to have a 
significant impact on mitochondrial fusion levels and mitochondrial translocation (Ni 
et al., 2015). Mitochondrial fission is mediated through the interactions of the 
Dynamin related protein 1 (DRP1) with mitochondrial fission protein 1 (hFIS1) and 
mitochondrial fission factor (MFF). DRP1 is initially recruited from the cytosol to the 
mitochondrial membrane under conditions of stress, and this prompts DRP1 to 
constrict the mitochondrial membrane which leads to division into daughter 
organelles.  
 
 
Figure 0.7: Microscopic presentation of mitochondrial morphology. Healthy mitochondria 
present as well defined interconnected networks indicative of fusion (Control), while ailing 
mitochondria present as fragmented networks indicative of fission (Doxo) (Parra et al., 2008). 
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These dynamic processes are regulated by mitochondrial biogenesis; a process 
which is defined as the growth and division of pre-existing mitochondria. 
Mitochondrial biogenesis itself is controlled by the peroxisome proliferator-activated 
receptor gamma co-activator (PGC-1α). As indicated in Fig. 1.6, PGC-1α interacts 
with nuclear transcription factors (NTFs) and stimulates mitochondrial biogenesis 
through the transcriptional regulation of the mitochondrial genome and mitochondrial 
proteins (Ventura-Clapier et al., 2008).  
As mitochondrial fusion and fission complement one another in a delicate balance, 
controlled by mitochondrial biogenesis, it has previously been observed that this 
balance is disturbed in many CVDs including cardiotoxicity (Parra et al., 2008). In 
these pathologies, the balance favours mitochondrial fission which induces 
mitochondrial membrane depolarization, due to hFIS1-linked Bax recruitment to the 
mitochondrial membrane and subsequent formation of pores within the mitochondrial 
membrane by Bax (Bae et al., 2000, Lee et al., 2004). This depolarization induces 
DRP1-dependent cytochrome c leakage and ultimately apoptosis induction (Zungu et 
al., 2011). Due to the high accumulation of DOX in cardiomyocytes as a result of 
binding to cardiolipin, the resulting oxidative stress and the uncontrolled fission, 
damaged mitochondria are the first histomorphological features of DOX-induced 
cardiotoxicity (Minotti et al., 1999). This damage, if unresolved could have 
catastrophic consequences for the cell and ultimately affect heart function as a 
whole.  
 
1.5 Mitochondrial associated degradation 
With the critical role that mitochondria play in cellular homeostasis, maintaining 
mitochondrial health is a major cellular priority. The regulation of mitochondrial 
proteins used to maintain mitochondrial quality and integrity has led scientists to 
believe that there is a mitochondrial-associated degradation pathway that plays this 
role. This degradation system is known the Ubiquitin Proteasome System (UPS) and 
serves as a quality control mechanism not only for this organelle, but also for the cell 
in its entirety.  
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The UPS is a known proteolytic pathway that tags proteins with ubiquitin molecules 
and degrades them via its catalytic centre, the 26S proteasome made up of a 20S 
core subunit and a 19S regulatory subunit (Ciechanover, 1994). In the presence of 
ATP, the first step in this process begins when an ubiquitin moiety is transferred to 
the ubiquitin conjugating enzyme (E2) by the ubiquitin activating enzyme (E1). In the 
second step, ubiquitin ligases (E3) cause ubiquitin chain ligation onto the targeted 
protein (Fig. 1.8). This process of tagging proteins with ubiquitin molecules is 
repeated until the proper conformation of ubiquitin molecules is formed and the 
ubiquitin molecules are attached to the correct lysine residue. In this case for 
degradation to take place, poly-ubiquitination needs to occur at lysine 48. It is only in 
the third and final step does the 26S proteasome target the ubiquitinated proteins for 
degradation while the ubiquitin molecules are recycled (Jiang et al., 2015). Bearing 
in mind that there are numerous E3 ligases, this review will highlight two such E3 
ligases that are considered important in the context of mitochondrial dysfunction 
during cardiotoxicity. 
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Figure 0.8: The Ubiquitin Proteasome System. Ubiquitin molecules get transferred to the E2 
enzyme by the E1 enzyme in an ATP-dependent fashion. This ubiquitin conjugated E2 enzyme then 
binds an E3 enzyme which is also bound to the substrate protein and then the E3 enzyme facilitates 
transfer of ubiquitin from the E2 to the substrate. The tagged substrate is recognized by the 26S 
proteasome and degraded whilst the ubiquitin molecules are recycled. DUBs interfere in this process 
by removing ubiquitin molecules from tagged substrate proteins. Abbreviations: DUBs - 
Deubiquitinating enzymes, E1 - ubiquitin activating enzyme, E2 - ubiquitin conjugating enzyme, E3 – 
ubiquitin ligase, Lys - lysine, Ub – ubiquitin. Adapted from Nandi et al., (2006). 
 
1.5.1 PINK1 and Parkin 
Severely polarized mitochondria that are marked for degradation through mitophagy 
accumulate PTEN-induced putative kinase 1 (PINK1); a serine/threonine kinase that 
contains an N-terminal mitochondrial targeting sequence (MTS) and a 
transmembrane segment (TM). When PINK1 associates with healthy mitochondria, 
its MTS translocates across the mitochondrial membrane where it gets cleaved by 
DUBs 
Ub 
Ub Ub 
Ub 
26s PROTEASOME 
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the mitochondrial processing peptidase (MPP) leaving the remaining TM cleaved by 
presenilin-associated rhomboid-like (PARL). This causes the dissociation of PINK1 
from the mitochondria and its degradation by the UPS. However, when PINK1 
associates with polarized mitochondria, the MTS is unable to translocate through the 
mitochondrial membrane and thus PARL becomes inactivated. As such, an intact 
PINK1 associates with translocases of the outer membrane (TOM) via TOMM7 to 
form a complex which homodimerizes PINK1 to activate its kinase function (Youle et 
al., 2012; Eiyama & Okamoto, 2015). Once the PINK1 complex is stabilized on the 
outer mitochondrial membrane, it recruits Parkin, an E3 ubiquitin ligase. Parkin 
subsequently becomes phosphorylated and activated by PINK1, which then 
ubiquitinates mitochondrial proteins, particularly those responsible for mitochondrial 
fusion. The degradation of these fusion proteins thus throws the mitochondrial 
dynamic balance in favour of fission (Eiyama & Okamoto, 2015). Additionally, Parkin 
also enhances mitophagy by recruiting p62 (sequestosome 1, SQSTM1), which 
interacts with LC3, a protein that is integral in autophagosome formation during 
mitophagy (Ni et al., 2014).  
 
1.5.2 MARCH5 
MARCH5 is a transmembrane protein expressed on the outer mitochondrial 
membrane. It is a relatively novel protein known to localise with MFN2 and DRP1. 
Being a RING-finger E3 ubiquitin ligase, it is an integral membrane protein which 
when over expressed triggers mitochondrial fusion, resulting in elongated 
mitochondria with an extensive network. However, when MARCH5 is down-regulated 
or when mutated forms are expressed; increased fragmentation is observed 
indicating elevated mitochondrial fission (Nakamura et al., 2006). They concluded 
that MARCH5 ubiquitinates DRP1 for proteasomal degradation, which in turn 
reduces fission in a MFN2-dependent manner. This suggested that MARCH5 could 
also play a role in the regulation of fusion.   
Interestingly, Karbowski, (2011) demonstrated that MARCH5 induced lysine-63 
linked regulatory ubiquitination of DRP1, an observation supported by Neutzner et 
al., (2008). In an earlier study by Karbowski et al., (2007), RING finger mutations of 
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MARCH5 led to abnormally elongated mitochondria indicative of fusion. According to 
this study, MARCH5 regulates the sub-cellular trafficking of DRP1 and while the 
over-expression of MARCH5 causes no changes in mitochondrial morphology, 
mitochondrial network elongations are observed when MARCH5 is inhibited. This 
points to an interdependent association between DRP1 and MARCH5 rather than a 
direct association because when DRP1 is ectopically expressed, it leads to a 
reduction or reversal in the abnormalities induced by the expression of MARCH5 
mutants (Karbowski et al., 2007). The mechanisms by which PINK1/Parkin and 
MARCH5 lead to the regulation of mitochondrial dynamics and morphology indicate 
the influence that these E3 ubiquitin ligases have on the functioning these organelles 
and highlights their importance during UPS activity in the control of mitochondrial 
homeostasis.  
The tagging of proteins ubiquitin molecules can have different outcomes. As 
mentioned previously, poly-ubiquitination of proteins on lysine-48 leads to 
proteasomal degradation, whereas mono-ubiquitination on lysine-63 leads to 
regulation of protein activities through inhibition, activation or transport within the cell. 
It is believed that the most likely mechanism by which ubiquitin-tagged proteins are 
transported out of the mitochondrial membrane is via translocation enabled by the 
ATPases, which are associated with diverse cellular activities. Once in the cytosol, 
the proteins can then be degraded by the 26S proteasome (Neutzner et al., 2008). In 
the context of DOX-induced cardiotoxicity, research conducted by our group has 
previously demonstrated that therapeutically relevant doses of DOX can either 
augment or diminish proteasomal activity, and this is associated with an increase the 
expression of ubiquitin E3 ligases Parkin and March5 (Opperman, 2015). The 
elevation of these E3 ligases induces proteasomal degradation of fusions proteins 
and consequently fission ensues in cardiac mitochondria. The influence of E3 ligases 
is not only limited to mitochondrial E3 ligases, but also to ligases that target proteins 
involved in the regulation of ROS, apoptosis and other cellular processes (Ranek & 
Wang, 2009). Considering that ubiquitination is a reversible process regulated by de-
ubiquitinating enzymes (DUBs), it is thus plausible to speculate that the manipulation 
of these enzymes in preventing mitochondrial specific protein degradation is a viable 
option to promote healthy functional mitochondria and prevent cell death in an effort 
to improve survival. 
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1.6  De-ubiquitinating enzymes 
De-ubiquitinating enzymes (DUBs) are a group of enzymes whose main purpose is 
to remove ubiquitin molecules from ubiquitin tagged proteins (Fig. 1.8). There are ± 
100 known mammalian de-ubiquitinating enzymes and are classified into five main 
categories:  
i. Ubiquitin specific proteases (USPs) are the largest group of DUBs with ± 
60 USPs identified 
ii. Ovarian-tumour domain DUBs (OTU)  
iii. Machado-joseph domain DUBs (MJD) 
iv. Ubiquitin c-terminal hydrolases (UCHs) 
v. Zinc-dependent JAB1/MPN domain-associated metalloproteases (JAMM)  
The first four categories are thiol proteases, while the fifth has a domain called 
JAMM (JAB1/MPN/Mov34 metalloenzymes) (Endo et al., 2009). These enzymes are 
numerous and are highly expressed and thus ensure their specificity in vivo. A 
soaring number of disease states have been linked to dysfunctional or unexpressed 
DUBs. While dysfunctional DUBs have been linked with tumour cell survival in 
cancer patients, Ataxia, Alzheimer’s and other neurological disorder have been 
linked to defective DUBs (Yue et al., 2014). DUBs have a catalytic function and 
possess active sites specific for ubiquitin molecules and their target proteins. When 
bound to ubiquitin molecules on substrate proteins, they remove the ubiquitin 
molecule and the protein can function as normal. DUBs also associate with E3 
ligases independent of substrate proteins, for reasons that could include regulation 
of the E3 enzyme function, or an interdependent regulatory relationship between the 
E3 ligase and the specific DUB (Nijman et al., 2005). In the context of DOX-induced 
cardiotoxicity, there is little research that has been conducted to assess the role that 
these enzymes play in the broad context of cardiotoxicity; however, research has 
shown that a number of DUBs play a vital role in the more generalised mechanisms 
of mitochondrial homeostasis. With these mechanisms in mind, three DUBs have 
been identified that could prove crucial in this context: USP30, USP9x and USP36.  
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1.6.1 USP30 
USP30 is a DUB whose role is still being explored. Recently, Bingol et al., (2014) 
demonstrated that USP30 inhibits mitophagy by up to 70% and its over-expression 
induces the de-ubiquitination of proteins ubiquitinated by Parkin. It was further 
demonstrated that the knockdown of USP30 stimulates mitophagy, leading to the 
conclusion that USP30 de-ubiquitinates mitochondrial proteins and as a result 
increases mitochondrial fusion while opposing fission-associated mitophagy. In 
support of this notion, Nakamura et al., (2008) reported that the knockdown of 
USP30 generates to elongated mitochondria and the development of extensive 
networks. However when this knockdown was accompanied by the knockdown of 
the mitofusin proteins, the increase in mitochondrial fusion that was initially observed 
was inhibited, implying that USP30 promotes fusion in a mitofusin-dependent 
manner. Interestingly, a diterpenoid derivative, S3, also elevated mitochondrial 
fusion and rescued previously lost mitochondrial DNA in vitro (Yue et al., 2014). The 
positive results were attributed to the down-regulation of USP30 by S3 since 
mitofusin or OPA1 mutant cells demonstrated no increase in mitochondrial fusion. 
Although the above described study was conducted in the neurological context, 
extensive research remains to be conducted as USP30 inhibition also induced Lys 
63 ubiquitination of the mitofusins.  
 
1.6.2 USP9x 
USP9x stabilizes E3 ligases, and de-ubiquitinates proteins that are important for cell 
polarity and adhesion (Nathan et al., 2008). It is considered important in this context 
as it has been associated with the anti-apoptotic protein MCL-1. MCL-1, a member 
of the Bcl-2 family of apoptosis-regulating proteins, is ubiquitinated during cellular 
stress by the E3 ligase MULE (MCL-1 Ubiquitin Ligase). Therefore, USP9x de-
ubiquitinates MCL-1 by removing lysine 48 linked ubiquitin molecules tagged by 
MULE and inhibits its degradation (Karbowski & Youle, 2011). USP9x has also been 
shown to play a significant role in the increased expression of MARCH7, a protein 
closely related to MARCH5 but functions as a regulator of T-lymphocytes and 
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cytokine signalling (Nathan et al., 2008). However, for this study, MARCH7 will not 
be explored further. 
1.6.3 USP36 
USP36 has previously been described to play a role in oxidative stress levels of the 
cell by localizing to the nucleoli. This enzyme has been found to interact with a major 
mitochondrial anti-oxidant, MnSOD (manganese superoxide dismutase, SOD2) (Kim 
et al., 2011). MnSOD undergoes poly-ubiquitination and eventual degradation during 
conditions of stress by unknown E3 ligases. USP36 thus de-ubiquitinates MnSOD 
and prevents its degradation which could prove beneficial in this context. Keeping 
anti-oxidants at optimum levels is important seeing that MnSOD reduces the levels 
of the superoxide anions which are major contributors of oxidative stress (Kim et al., 
2011). In a different context, USP36 has also been shown to regulate autophagic 
activity and thereby possibly influences mitophagic activity. Evidence of this was 
provided by Taillebourg and colleagues (2012) who demonstrated that USP36 
inhibition stimulates elevated autophagy which when excessive is detrimental in this 
context.  
 
1.7 Study Rational 
While extensive research has been conducted on various facets of DOX-induced 
cardiotoxicity, very little attention has been paid to research investigating the 
potential role that DUBs have in the ability to reduce the cardiomyopathies 
associated with DOX treatment. Much of the effort has been concentrated on the 
oxidative stress hypothesis and the concept of anti-oxidants serving as adjuvant 
therapies to little success (Van Dalen et al., 2005); whereas others have focused on 
anthracycline derivatives and the use of iron-chelating agents. Despite these efforts, 
all have faced road blocks resulting in very little sustainable clinical success.  
As observed above, cardiac mitochondria play a central role in the development of 
cardiotoxicity (Parra et al., 2008), and key to this is mitochondrial dynamics regulated 
by mitochondrial fusion and fission. This process becomes dysregulated in the 
presence of DOX via oxidative stress, the association of DOX with cardiolipin, as 
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well as the degradation of fusion proteins by the UPS, whilst promoting fission. 
Therefore, by investigating the role of DUBs in this context, this study anticipates that 
the results obtained will lead to a better understanding of the mechanism/s that 
induce cardiotoxicity and identify avenues for exploration for therapeutic intervention. 
 
1.8 Hypothesis 
In light of the above information, this study hypothesizes that manipulating the 
expression of de-ubiquitinating enzymes reduces mitochondrial dysfunction by 
promoting fusion and improving ATP synthesis in the context of chronic DOX-
induced toxicity. 
 
1.9 AIMS 
 Develop models of chronic DOX-induced cytotoxicity and cardiotoxicity 
 Establish the role of specific DUBS in this context 
1.10 OBJECTIVES 
 To establish chronic model of DOX-induced toxicity  
o in vitro (cytotoxicity) and in vivo (cardiotoxicity) 
 To determine the relative expression of DUBs during chronic DOX-induced 
toxicity in vitro and in vivo 
 To assess the relative expression of downstream proteins associated with the 
specific DUBs in vitro and in vivo 
 To determine the relative protein expression of downstream proteins following 
the down-regulation DUBs (via SiRNA) in vitro 
 To establish the effect of down-regulation of these DUBs on mitochondrial 
health by measuring mitochondrial toxicity, ATP synthesis and mitochondrial 
morphology 
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 MATERIALS and METHODS 
 
2.1  H9C2 CARDIOMYOBLAST CELL CULTURE 
H9C2 rat cardiomyoblasts (European Collection of Cell Cultures, Salisbury, UK) 
were utilized for the duration of this study. These cells are a commonly used cell line 
in this context as they are robust, easy to maintain and have the advantage of being 
an in vitro alternative. Moreover, these cells have previously been shown to respond 
in a similar fashion to primary cardiomyocytes to hypertrophic stimuli, thus validating 
their importance as a model for in vitro studies investigating various heart diseases 
(Watkins et al., 2011). The cells were seeded in T25 culture flasks (1,000,000 cells) 
and 6-well plates (200,000 cells per well). Once seeded, the cells were cultured 
under sterile conditions in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, 
41965-039) that was supplemented with 10% Fetal Bovine Serum (FBS) (Biocom 
Biotech, FBS-G1-12A) and 1% Penicillin/Streptomycin (ThermoFisher Scientific, 
15140-122). The cells were maintained at 37 oC in a humidified atmosphere of 95% 
oxygen (O2) and 5% carbon dioxide (CO2). Cellular health was maintained by 
refreshing culture media every 48 hours (hrs) and cells were sub-cultured and 
seeded into culture plates or flasks for further experimentation once 70% confluence 
was attained (for detailed methods, refer to Appendix B, pg. 83). 
 
2.1.1  Doxorubicin treatment (in vitro model) 
The anthracycline antibiotic DOX (Sigma-Alrich, D1515) was used as the 
chemotherapeutic agent to induce cytotoxicity in this model. This anthracycline 
antibiotic is often used as the first-line treatment for various types of cancers (Minotti 
et al., 2004). A 3.4 mM stock was prepared in sterile DMEM and stored in the dark 
(light sensitive) at -20 oC until required. As this study attempted to simulate chronic 
cytotoxicity, cells were treated daily with 0.2 µM DOX for 120 hrs (5 days). This was 
done to take into account the cumulative dose dependent characteristics of the 
chronic form of cytotoxicity. Therefore, after treatment was complete, the total 
cumulative dose of DOX would be 1.0 µM (0.2 µM x 5 days = 1.0 µM). This 
cumulative dose also falls within the clinically relevant DOX concentration 
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appropriate for in vitro models (Minotti et al., 2004) (for detailed methods, refer to 
Appendix B, pg. 86).  
2.2  Animal Care and Ethical Consideration (in vivo model) 
2.2.1  Study Approval 
This animal study was reviewed and approved by the Stellenbosch University Animal 
Ethics committee (SU-ACUD 15-00038). The guidelines followed are those from the 
South African National Standards 10386:2008. (Appendix D, pg. 101) 
Eight four week old male wild-type Sprague Dawley rats, of average weight 120g 
were purchased from the Stellenbosch University animal unit. The animals were 
randomly housed 3-4 per cage (sterile and ventilated) and were acclimatized to the 
new environment for one week before experimentation commenced. The 
temperature (21-25 oC) and 12-hour day/night cycles were controlled and constantly 
monitored by qualified animal house managers throughout the duration of the study. 
The animals were nourished with a constant supply of standard rat chow and water 
ad libitum. Environmental enrichment was achieved through the use of red Perspex 
tubing and shredded paper.  
 
2.2.2  DOX treatment 
Animal body weights were recorded three times a week each morning that injections 
were prepared. The animals were treated from five weeks of age with 2.5 mg/kg 
DOX over a period of eight weeks, resulting in a cumulative dose of 20 mg/kg. As 
mentioned previously, this work was conducted to simulate chronic DOX-induced 
cardiotoxicity and, in this model in particular, paediatric cancer survivors suffering 
from cardiotoxicity during their adult lives, considering that this is the group that is 
most affected by chronic cardiotoxicity (Choi et al., 2010). All injections were 
conducted via intraperitoneal (i.p) administration once a week. Since there were only 
two experimental groups, the control also received saline injections (i.p) as this was 
the solvent for the DOX. Although body weight measurements were taken three 
times a week, animals were observed daily by the researchers involved in this study. 
Considering the toxic nature of DOX, humane endpoints were put in place to as a 
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“cost to benefit” measure to ensure minimal animal suffering. The following 
observations were regarded as humane endpoints at which animals would be 
euthanized to prevent excessive suffering: 
 Loss of >15% body weight 
 Failure to eat or drink for a period >24 hrs 
 Continuous inflammation of the areas where DOX was injected 
 Signs of pain or discomfort (normal posture, clean coat and facial grimacing) 
 
2.2.3  Animal sacrifice and organ harvest 
One week after the last DOX injections (week 9), the animals were anesthetized (i.p) 
with a lethal dose of pentobarbitone (60 mg/kg). Once the pedal reflex was no longer 
evident, the hearts were excised, weighed and perfused. Therefore, all blood was 
removed during the perfusion process. Once completed, the hearts were frozen in 
liquid nitrogen and stored at -80 °C for further analysis. Repeated freeze-thaw cycles 
were avoided to prevent protein degradation and maintain tissue sample quality.  
Figure 2.1 below indicates the various experiments that were conducted in this study 
using the different in vitro and in vivo models and the techniques are briefly 
described below the figure. 
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Figure 0.1: Schematic diagram showing the approach used to achieve the research objectives 
 
2.3  Western Blotting 
 
2.3.1  Preparation of cell and tissue lysates 
Cell lysates: 24 hours after treatment, growth medium was removed and the 
monolayer of cells was washed with sterile ice-cold phosphate buffered saline (PBS). 
The cells were scraped off the surface of the flask or plates, after 50 µL radio-
immunoprecipitation assay (RIPA) buffer was added. This process was then followed 
by the transfer of cell/lysis buffer solutions into chilled Eppendorf tubes for 
sonification using an ultrasonic homogenizer (Misonix, Qsonica, USA). The cells 
were sonicated for ±10 seconds at amplitude of 10 m, after which the contents were 
centrifuged at 8000 rpm (5900 g) for 10 minutes. The pellet was discarded, and the 
supernatant was preserved for protein determination. All of the above was conducted 
on ice.  
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Tissue lysates: a similar process to the above was followed for the preparation of the 
tissue lysates, with minor modifications. Briefly, 250 µL RIPA was added to each 
thawed tissue sample placed into chilled test tubes. All samples were then 
homogenized with a polytron benchtop homogenizer (Kinematica, USA) separately 
for ±30 seconds at 30000 rpm (20124 g). Careful attention was paid during this 
process to avoid cross contamination between samples. The content of each test 
tube was transferred into chilled Eppendorf tubes for centrifugation (Labnet) (12000 
rpm/ 13300 g, 4oC, for 20 minutes). The pellet was discarded and the supernatant 
was preserved (for detailed methods, refer to Appendix B, pg. 87). 
2.3.2  Protein determination of cell and tissue lysates. 
Determination of protein concentration was performed using the Direct Detect ™ 
Spectrometer (Merck Millipore DDHW00010-WW Darmstadt, Germany). This system 
determines protein concentration within the ranges of 0.25 – 5 mg/mL accurately by 
measuring amide bonds in protein chains. As such, it accurately quantifies this 
intrinsic property of every protein without relying on amino acid composition, dye 
binding properties, or redox potential, eliminating the pitfalls of colorimetric assays 
such as the Bradford technique often used to determine protein concentrations. 2 µL 
of RIPA buffer (blank) was used to calibrate the system, where after 2 µL of each 
sample was also placed into an Assay-free card. The card was then inserted into the 
Direct Detect ™ machine, and protein concentration (mg/ml) was determined per 
sample. This process was conducted in triplicates (for detailed methods, refer to 
Appendix B, pg. 87).  
2.3.3  Sample preparation and gel electrophoresis 
50 µg protein from cells and 100 µg protein from tissue samples were subjected to 
polyacrylamide gel electrophoresis using 12% graded gels (Bio-Rad, 456-8084). The 
proteins were transferred onto polyvinylidinefluoride (PVDF) membranes (Bio-Rad, 
170-4156) and blocked in 5% milk for two hrs. PVDF membranes were incubated 
with specific primary antibodies overnight at 4 ⁰C in Tris-buffered saline tween 
(TBST). Following a few wash steps, the membranes were incubated in appropriate  
secondary antibodies (Table 2) for one hr at room temperature, where after the 
membranes were then processed for chemiluminescent detection using the clarity 
ECL substrate (Bio-Rad, 170-5061) in the Chemi-Doc™ XRS system (Bio-Rad, 
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USA). Band intensity quantification was conducted using ImageLab software version 
5.0 (for detailed methods, refer to Appendix B, pg. 88).  
 
Table 2: A list of various antibodies used throughout the study. 
 Primary antibodies 
Name Size (kD) Company Catalogue Number 
USP9x 270 Cell 
Signalling 
5751 
USP30 59 Santa 
Cruz 
Sc-109455 
USP36 123 Santa 
Cruz 
Sc-82104 
MCL1 40 and 32 Santa 
Cruz 
Sc-819 
MFN1 84 Abcam ab129154 
MFN2 86 Abcam ab124773 
SOD2 
(MnSOD) 
24 Cell 
Signalling 
1314S 
TOMM20 16 Cell 
Signalling 
42406 
β-actin 45 Cell 
Signalling 
5125 
 Secondary antibodies 
Anti-rabbit Cell 
Signalling 
7074 
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Donkey anti-goat Abcam ab97110 
 Fluorescent antibodies 
FITC Lifetech A-31577 
TxsRED Lifetech A-21432 
 
Also indicated are the companies where these were purchased from, as well as the catalogue 
numbers. Abbreviations: FITC: Fluorescein Isothiocyanate, MCL1: Myeloid Cell Leukaemia 1, MFN: 
Mitofusin, SOD: Superoxide Dismutase TOMM: Translocase of Outer Mitochondrial Membrane, 
TxsRED: Texas Red, USP: Ubiquitin Specific protease. 
 
2.4  Immunocytochemistry 
Cells were cultured, monitored and treated as previously described on micro cover 
slips in 6-well plates (200,000 cells per well). After treatment media was removed 
and the monolayer of the cells was washed twice with warm PBS. The coverslips 
were removed and placed onto glass slides where after they were washed twice in 
cold PBS, and then fixed for ten minutes at 37oC with 4% paraformaldehyde (Sigma, 
158127). The cells were permeated using 0.1% triton solution (Sigma, X-100) and 
then blocked with 5% donkey serum (Cell Tech, UK) for 30 minutes at room 
temperature. Cells were washed three times with cold PBS and then incubated with 
primary antibodies against USP36, USP30, MCL1, MFN1 and MFN2 overnight in a 
wet chamber at 4 oC. Following this incubation period, the cells were washed with 
cold PBS and incubated in secondary antibody (Donkey anti-goat, and rabbit anti-
mouse) for an hour at room temperature in a dark wet chamber and then stained 
with Hoechst (Thermofisher Scientific H1399) for ten minutes and then washed again 
with PBS. After this step, the coverslips were mounted onto glass slides using DAKO 
fluorescent mounting media (Diagnostech, s3022380), sealed with nail polish and 
then stored at -20 degrees in the dark until imaging (for detailed methods, refer to 
Appendix B, pg. 90 ). 
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2.4.1 Imaging 
Imaging was achieved using a Nikon eclipse E400 fluorescent microscope equipped 
with a DMX1200 CCD camera 200. Images were acquired through the Nikon plan 
Flour 10x and 40x objective lenses. Each experimental group consisted of three 
replicates and three random images were taken per replicate either at 10x or 40x 
magnification and these served as representative images per group. It must be noted 
that no quantification was conducted as this experiment served only as a visual 
supplementation to the data obtained from the western blots.  
 
2.5 Transfection with siRNA 
Transfection was performed on H9c2 cells at a transfection density of 2.5x105 
cells/mL by electroporation with the Neon® transfection system (Invitrogen 
MPK5000) and then seeded into 6 and 96-well plates. The cells were maintained in 
an incubator at 37o C, in a humidified atmosphere of 95% O2 and 5% CO2. 24 hours 
post siRNA administration, culture medium was replaced with fresh media, and 
maintained for 72 hours after which the cells were subjected to chronic DOX (0.2µM 
daily for 120 hrs) treatment and used for a toxicity assay or harvested for western 
blots. USP30 (SI01668807), USP36 (SI01661331), USP9x (SI101840363) siRNA 
and negative control (1027280) were purchased from Qiagen. The SiRNAs were 
used at a working concentration of 20 µM and diluted to 200 nM for transfection via 
electroporation (for detailed methods, refer to Appendix B, pg. 92).  
2.6 Mitochondrial Toxicity 
Mitochondrial toxicity was measured using the MitochondrialToxGlo ™ Assay 
(Promega G8000). This assay assesses mitochondrial dysfunction as a result of 
xenobiotic exposure. It measures membrane integrity first using bis-AAF-R110, a 
fluorogenic peptide substrate to measure “dead cell protease activity”, which is the 
activity of a specific protease associated with necrosis. The intact membranes of 
healthy cells are impermeable to the substrate, and as such non-viable cells produce 
higher signals. It also measures ATP concentration through an ATP detection 
reagent which causes cell lysis and the generation of a luminescent signal 
proportional to the ATP present.  
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Following transfection, 10000 cells were seeded at a density of 5 x 106 cells/mL in a 
96-well plate for 48 hrs and treated as previously described. The assay was 
conducted and measured according to the manufacturers’ protocol, where after the 
fluorescent signal produced was measured with a FLK800 fluorescence microplate 
reader (Bio-tek, USA) and luminescence measured using the GloMax® 96 Microplate 
Luminometer (Promega, USA) (for detailed methods, refer to Appendix B, pg. 94).  
2.7 Mitochondrial Morphology 
Mitochondrial shape often regulates life or death signals and this study found it 
appropriate to assess their morphology under these conditions. Following 
transfection, cells were seeded (10000 cells per well) and treated as previously 
described in Nunc Lab-Tek™ 8-well chambers (ThermoFisher Scientific, 154534). 
Once treatment was complete, cells were washed with sterile PBS and incubated 
with MitoTracker Green™ (ThermoFisher Scientific, M-7514) and Hoechst for 20 
mins. MitoTracker Green™ (0.5 µM) binds to free sulfhydryl proteins present in 
mitochondria, and produces a green fluorescent signal which can be visualized by 
fluorescence microscopy. Cells were visualised live at 60x magnification with the 
OLYMPUS Plan Apo N60x/1.4 oil objective of the Olympus IX81 wide field 
fluorescent microscope (Zeiss). Z-stack images using appropriate upper and lower 
focal points were acquired and images were processed and displayed at maximum 
intensity projection using the Cell^R software (for detailed methods, refer to 
Appendix B, pg. 92).  
 
2.8 Statistical analysis 
Data are presented as mean ± standard error of the mean (SEM). A p-value of less 
than (<) 0.05 was considered statistically significant. All data was normalized to a 
percentage of the respective control groups. Experiments involving two groups were 
analysed with the Student’s unpaired t-test, followed by the Mann-Whitney test. 
Experiments with more than two groups were analysed through one-way ANOVA 
with Bonferroni post-hoc correction using Graph-pad Prism ™ software version 5 for 
visual representation and statistical significance. 
 
Stellenbosch University  https://scholar.sun.ac.za
33 
 
 RESULTS 
 
3.1 Protein expression 
 
To determine baseline protein expression of the different DUBs and their 
downstream proteins, western blotting was performed on both the cell lysates (in 
vitro) and tissue samples (in vivo). This was deemed important to establish the effect 
that DOX induces on these proteins when compared to the controls.  
 
3.1.1 USP9x and MCL-1 
USP9x, a 270 kD protein is a ubiquitin specific protease responsible for the de-
ubiquitination of MCL-1, an important protein involved in the regulation of apoptosis. 
Our results demonstrate that chronic DOX treatment significantly increased the 
expression of USP 9x in vitro (337.2 ± 41.6%, p<0.05) and in vivo (194.6 ± 15.2%, 
p<0.05) when compared to the control (Fig. 3.1). 
 
Figure 0.1: Relative protein expression of USP9x following prolonged treatment with DOX in 
vitro and in vivo.  
In Vitro 
Control DOX Control DOX 
In Vivo 
β -actin 
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H9C2 cells were treated with 0.2 µM DOX daily for 120 hrs, and Sprague-Dawley rats treated i.p. with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM (n = 3-5) *p<0.05 vs. control. β-
actin was used as a loading control. Abbreviations: DOX - Doxorubicin USP - Ubiquitin specific 
protease. 
Myeloid Cell Leukemia 1 (MCL-1) is an anti-apoptotic protein that is de-ubiquitinated 
by USP9x, and therefore, its expression is important for this context. While MCL-1 is 
ubiquitinated for degradation, it also undergoes post-translational modification, 
resulting in two fragments that have opposing functions (Bae et al., 2000). On the 
one hand, the anti-apoptotic long fragment of MCL-1 (MCL-1L) was significantly 
reduced in vitro (43.18 ± 16.3%, p< 0.05) in the DOX treated group, whereas only a 
trend towards a decrease was observed in vivo when compared to the control (Fig. 
3.2). 
 
Figure 0.2:  Relative protein expression of MCL-1L following prolonged treatment with DOX in 
vitro and in vivo.  
H9C2 cells were treated with 0.2 µM DOX daily for 120 hrs, and Sprague-Dawley rats treated i.p. with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM (n = 3-5). *p<0.05 vs. control. 
β-actin was used as a loading control. Abbreviations: DOX - Doxorubicin MCL-1L - Myeloid Cell 
Leukaemia-1 long-fragment. 
Control DOX Control DOX 
In Vitro In Vivo 
β -actin 
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On the other hand, the pro-apoptotic short-fragment of MCL-1 (MCL-1S) was 
significantly up-regulated in vivo (188.7 ± 12.7%, p<0.05), while a trend towards an 
increase was observed in vitro (Fig. 3.3). The results are in contrast to those 
obtained for the MCL-1 long fragment, suggesting that the observed increase in 
USP9x is targeted for the de-ubiquitination of MCL-1L rather than MCL-1S following 
post translational modification. This further illustrates how DOX induces apoptosis 
via the promotion of pro-apoptotic factors.  
 
Figure 0.3: Relative protein expression of MCL-1S following prolonged treatment with DOX in 
vitro and in vivo. 
H9C2 cells were treated with 0.2 µM DOX daily for 120 hrs, and Sprague-Dawley rats treated i.p. with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM (n = 3-5). *p<0.05 vs. control. 
β-actin was used as a loading control. Abbreviations: DOX - Doxorubicin MCL-1S - Myeloid Cell 
Leukaemia-1 short-fragment. 
 
 
 
 
Control DOX 
In Vitro In Vivo 
Control DOX 
β -actin 
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3.1.2 USP30, MFN1 and MFN2 
 USP30 is an enzyme known to interact with both mitofusin proteins (MFN1 and 
MFN2). Its function is rather controversial as some studies indicate it is purely 
regulatory (Yue et al., 2014), while others show either mitochondrial fusion inhibition 
(Nakamura et al., 2008) or mitochondrial fusion promotion (Bingol et al., 2014). Our 
data demonstrates substantial reduction of this de-ubiquitinating enzyme during DOX 
treatment in vitro (45.2 ± 13.1%, p<0.05) and in vivo (37.3 ± 7.5%, p<0.05) as 
indicated in (Fig. 3.4). This may either imply that USP30 is itself degraded or its 
synthesis is inhibited.   
 
Figure 0.4: Relative protein expression of USP30 following prolonged treatment with DOX in 
vitro and in vivo. 
H9C2 cells were treated with 0.2 µM DOX daily for 120 hrs, and Sprague-Dawley rats treated i.p. with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM (n = 3-5). *p<0.05 vs. control. 
TOMM20 was used as a loading control. Abbreviations: DOX - Doxorubicin USP - Ubiquitin specific 
protease. 
 
 
Control DOX 
In Vitro In Vivo 
Control DOX 
TOMM20 
Stellenbosch University  https://scholar.sun.ac.za
37 
 
Considering that USP30 was significantly reduced, it comes as no surprise that 
MFN1 was also significantly diminished in vitro (23.9 ± 11.9%, p<0.05) and in vivo 
(58.3 ± 4.9%, p<0.05) when compared to the controls (Fig. 3.5). These results 
indicate that MFN1 is tagged with ubiquitin molecules by E3 ligases and 
subsequently degraded due to the downgraded levels of USP30 and thus no 
inhibition of ubiquitination; hence degradation.  
 
 
 
Figure 0.5: Relative protein expression of MFN1 following prolonged treatment with DOX in 
vitro and in vivo. 
H9C2 cells were treated with 0.2 µM DOX daily for 120 hrs, and Sprague-Dawley rats treated i.p. with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM (n = 3-5). *p<0.05 vs. control. 
TOMM20 was used as a loading control. Abbreviations: DOX – Doxorubicin, MFN1 - Mitofusin 1. 
 
 
An unexpected result for baseline MFN2 protein expression was obtained in the in 
vitro model where significantly elevated levels of this protein (259.2 ± 15.4%, p<0.05) 
In Vitro In Vivo 
TOMM20 
Control DOX Control DOX 
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were observed. This was surprising considering the fact that USP30 targets both 
mitofusin proteins during de-ubiquitination. In contrast however, the results of the in 
vivo model (68.0 ± 3.6%, p<0.05) echoed those observed for MFN1 (Fig. 3.6).   
 
 
Figure 0.6: Relative protein expression of MFN2 following prolonged treatment with DOX in 
vitro and in vivo. 
H9C2 cells were treated with 0.2 µM DOX daily for 120 hrs, and Sprague-Dawley rats treated i.p. with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM (n = 3-5). *p<0.05 vs. control. 
TOMM20 was used as a loading control. Abbreviations: DOX – Doxorubicin, MFN2 - Mitofusin 2. 
 
3.1.3 USP36 and SOD2 
The third de-ubiquitinase of interest in this study is USP36, known to remove 
ubiquitin molecules from SOD2 (MnSOD). While its role in this context is yet to be 
elucidated, the E3 ligase responsible for ubiquitinating SOD2 is currently unknown. 
As indicated in Fig. 3.7., no significant changes in the expression of USP36 were 
observed when the two groups were compared to one another in both models used.  
Control DOX 
In Vitro In Vivo 
Control DOX 
TOMM20 
Stellenbosch University  https://scholar.sun.ac.za
39 
 
 
 
Figure 0.7: Relative protein expression of USP36 following prolonged treatment with DOX in 
vitro and in vivo. 
H9C2 cells were treated with 0.2 µM DOX daily for 120 hrs, and Sprague-Dawley rats treated i.p. with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM (n = 3-5). β-actin was used as 
a loading control. Abbreviations: DOX: Doxorubicin USP: Ubiquitin Specific Protease 
 
SOD2 (MnSOD) plays a vital role in the modulation of oxidative stress due to its 
ROS scavenging properties. Mainly localised to the mitochondria (Van Remmen et 
al., 2003), they serve as one of the many anti-oxidants available in a cell to protect 
against oxidative damage. While no substantial changes were observed in vivo (Fig. 
3.8), SOD2 was substantially elevated in response to DOX in vitro (336.9 ± 45.5%, 
p<0.05). DOX is notorious for its ROS producing properties, and therefore this 
increase in SOD2 implies a compensatory response from the cells to the augmented 
oxidative stress conditions by increasing their anti-oxidant defences.  
Control DOX Control DOX 
In Vitro In Vivo 
β -actin 
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Figure 0.8: Relative protein expression of SOD2 following prolonged treatment with DOX in 
vitro and in vivo. 
H9C2 cells were treated with 0.2 µM DOX daily for 120hrs, and Sprague-Dawley rats treated i.p with 
2.5 mg/kg DOX for 8 weeks. Results are represented as mean ± SEM, (n=3-5). *p<0.05 vs control. 
TOMM20 was used as a loading control. Abbreviations: DOX - Doxorubicin SOD - Superoxide 
Dismutase 
 
 
 
 
 
 
 
 
 
Control DOX Control DOX 
In Vitro 
In Vivo 
TOMM20 
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3.2 Immunocytochemistry 
In an effort to re-enforce the results obtained via western blotting, and to obtain the 
relative localization of the DUBs relevant in this study, immunocytochemistry was 
performed in vitro and visualised by fluorescence microscopy as indicated in the 
methods. It should be noted that only USP30 and USP36 were assessed as no 
appropriate antibody for USP9x for this specific experiment was available at the time. 
No quantification of this data was conducted and representative images are 
displayed. 
 
3.2.1 USP30 
According to our results (Fig. 3.9), USP30 appears to be highly expressed under 
control (untreated) conditions than under DOX treatment conditions. This was 
expected as USP30 regulates the degradation (de-ubiquitination) of mitofusin 
proteins (MFN1 and MFN2) (Nakamura et al., 2008). On the contrary, the fluorescent 
signal for this DUB was significantly reduced during DOX treatment, indicating that 
ubiquitination occurred and degradation ensued. It is clear from the images below 
that USP30 not only localises within the nucleus (encircled), it also appears to 
localise around the peri-nuclear region (arrows) under control conditions. Since the 
nucleus is surrounded by the endoplasmic reticulum and mitochondria (Preuss et al., 
1991; de Brito & Scorrano, 2008), the most likely organelle that this enzyme would 
localize with is the mitochondrion. In the presence of DOX however, no localization 
within the nucleus was observed. The results obtained in this experiment reaffirm 
those acquired by western blotting. 
Stellenbosch University  https://scholar.sun.ac.za
42 
 
 
Figure 0.9: Immunofluorescent images showing relative protein expression of USP30 during 
untreated and treated conditions with DOX in vitro. 
H9C2 cardiomyoblasts were treated with 0.2 µM DOX daily for 120 hrs (Blue - nucleus, Red - 
USP30). Peri-nuclear localisation is indicated by arrows (yellow) and localisation within the nuclear 
region is indicated by circles (white). Abbreviations: USP - Ubiquitin Specific Protease, DOX - 
Doxorubicin. Magnification = 40x, Scale bar = 25 µm. 
 
3.2.2 USP36 
While the western blot experiments revealed no significant results in terms of relative 
USP36 protein expression, the fluorescent images displayed in Fig. 3.10 tell a 
different story. Under control conditions, it was found that a generally low fluorescent 
signal for USP36 was observed in the cytosol, and in some areas (encircled) 
appears to be quite prominent. Interestingly, during DOX treatment, USP36 
accumulates within specific cytosolic regions and appear as protein aggregates. 
These aggregates produced an intense fluorescent signal that would otherwise not 
be recognized in the absence of DOX. These results imply that in response to DOX-
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induced oxidative stress, cells trigger enhanced USP36 expression for de-
ubiquitination of SOD2 (MnSOD) as a defence mechanism to protect against the 
damaging effects of ROS. 
 
Figure 0.10: Immunofluorescent images showing relative protein expression of USP36 during 
untreated and treated conditions with DOX in vitro. 
H9C2 cardiomyoblasts were treated with 0.2 µM DOX daily for 120 hrs (Blue - nucleus, Red - USP36 
Peri-nuclear localisation is indicated by arrows (yellow) and localisation within the nuclear region is 
indicated by circles (white). Abbreviations: USP - Ubiquitin Specific Protease, DOX - Doxorubicin. 
Magnification = 40x, Scale bar = 25 µm. 
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3.3 SiRNA (Down-regulation) of de-ubiquitinating enzymes 
Now that this study has addressed the first three aims from the experiments 
described above, we aimed to determine the effects of various mitochondrial 
parameters during DOX treatment when each of the DUBs were down-regulated 
using SiRNA. To make sure that successful down-regulation was achieved; western 
blotting was again used to determine relative protein expression of these DUBs and 
their downstream targets. 
 
3.3.1 USP9x and MCL1 
USP9x was successfully knocked down when the protein expression levels were 
compared to the control (Fig. 3.11A). To then determine what effect down-regulation 
of USP9x had on its target MCL1 in the presence or absence of DOX, both MCL1 
fragments were assessed. On the one hand, the long-fragment of MCL (MCL-1L) 
was elevated (207.1 ± 25.6%, p<0.001) in the absence of DOX when compared to 
the control (100.0 ± 9.1%), and a modest increase was observed in the presence of 
DOX when compared to the DOX group without down-regulation (Fig. 3.11B). On 
the other hand, when USP9x was knocked down, the short-fragment of MCL1 (MCL-
1S) showed a trend towards increased expression versus the control. However, in 
the presence of DOX, MCL-1S was significantly reduced (84.6 ± 9.6%, p<0.05) 
versus the DOX group without down-regulation (158.2 ± 16.9%) (Fig. 3.11C). These 
results are promising seeing that MCL-1L which was modestly increased in this case 
is anti-apoptotic, whilst pro-apoptotic MCL-1S was reduced. 
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Figure 0.11: Relative USP9x protein expression following SiRNA knockdown in the absence or 
presence of DOX in vitro 
 (A) USP9x known-down was achieved by electroporation using SiRNA, where after H9C2 
cardiomyoblasts were treated with 0.2 µM DOX daily for 120 hrs. (B) Relative protein expression of 
MCL-1L after SiRNA (USP9x) treatment in the absence or presence of DOX. (C) Relative protein 
expression of MCL-1S after SiRNA (USP9x) treatment in the absence or presence of DOX. Results 
are represented as mean ± SEM (n = 3), *p<0.05, **p<0.001 vs. Control and 
#
p<0.05 vs. DOX. β-actin 
was used as a loading control. Abbreviations: DOX - Doxorubicin, SiRNA - Silencing RNA, USP9x - 
Ubiquitin specific protease 9x, MCL-1L – Myeloid Cell Leukemia - 1 long-fragment, MCL-1S – Myeloid 
Cell Leukemia - 1 short-fragment, KD – knock-down. 
  
 
3.3.2 USP30, MFN1 and MFN2 
USP30 was also successfully knocked down when compared to the control (Fig 
3.12A). When compared to the control (100.0 ± 3.3%), knocking down USP30 led to 
significantly reduced MFN1 expression (73.0 ± 8.7%, p<0.05) (Fig. 3.12A) under 
these conditions. This study further demonstrated that down-regulating USP30 in 
DOX treated cells, also contributed to significantly reduced MFN1 expression (67.6 ± 
9.4%, p<0.05) versus the control group (Fig. 3.12B). Conversely, MFN2 was 
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significantly up-regulated (640.7 ± 112.2%, p<0.001) when USP30 was not present 
compared to the control group (100.0 ± 11.1%), and remained up-regulated by 
USP30 down-regulation, though to a lesser extent (468.1 ± 91.4%, p<0.05) in the 
presence of DOX when compared to the control group as well (Fig. 3.12C). The 
findings described here advance our previous theory that USP30 rather de-
ubiquitinates MFN1 and protects it from degradation rather than MFN2. 
 
Figure 0.12: Relative USP30 protein expression following SiRNA knockdown in the absence or 
presence of DOX in vitro. 
 (A) USP30 known-down was achieved by electroporation using SiRNA, where after H9C2 
cardiomyoblasts were treated with 0.2 µM DOX daily for 120 hrs. (B) Relative protein expression of 
MFN1 after SiRNA (USP30) treatment in the absence or presence of DOX. (C) Relative protein 
expression of MFN2 after SiRNA (USP30) treatment in the absence or presence of DOX. Results are 
represented as mean ± SEM (n = 3), *p<0.05, **p<0.001 vs. Control. TOMM20 was used as a loading 
control. Abbreviations: DOX - Doxorubicin, SiRNA - Silencing RNA, USP30 - Ubiquitin specific 
protease 30, MFN – Mitofusin, KD – knock-down. 
 
3.3.3 USP36 and SOD2 (MnSOD) 
USP36 plays an important role in the regulation and preservation of SOD2. It de-
ubiquitinates this anti-oxidant and consequently extends its half-life (Kim et al., 
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2011). This is essential for the regulation of cellular anti-oxidant defences against the 
damaging effects of oxidative stress. While this study previously indicated no 
significant changes in USP36 protein expression in vitro and in vitro (Fig. 3.7) in the 
context of DOX-induced toxicity, we were able to show that SOD2 expression was 
significantly increased during pro-longed DOX treatment. The knock-down of USP36 
resulted in no substantial change in SOD2 protein expression when compared to the 
control (Fig. 3.13A). However when DOX was introduced, SOD2 was substantially 
increased (500.0 ± 82.3%, p<0.01) versus the DOX group (245.5 ± 24.6%) without 
down-regulation (Fig. 3.13B). It thus becomes apparent that while literature 
acknowledges the role (de-ubiquitination) of USP36 on SOD2 (Kim et al., 2011), the 
results obtained in this experiment indicate their relationship is not as direct as 
previously thought. 
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Figure 0.13: Relative USP36 protein expression following SiRNA knockdown in the absence or 
presence of DOX in vitro. 
 (A) USP36 known-down was achieved by electroporation using SiRNA, where after H9C2 
cardiomyoblasts were treated with 0.2 µM DOX daily for 120 hrs. (B) Relative protein expression of 
SOD2 (MnSOD) after SiRNA (USP36) treatment in the absence or presence of DOX. Results are 
represented as mean ± SEM (n = 3). **p<0.01 vs. Control and 
#
p<0.05 vs. DOX. β-actin and TOMM20 
was used as a loading controls. Abbreviations: DOX - Doxorubicin, SiRNA - Silencing RNA, USP36 - 
Ubiquitin specific protease 36, MnSOD – manganese superoxide dismutase, SOD – superoxide 
dismutase KD – knock-down.  
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3.3 Mitochondrial morphology during SiRNA treatment of de-
ubiquitinating enzymes 
Mitochondrial morphology is regulated by the dynamic processes of mitochondrial 
fusion and fission (Hom & Sheu, 2009); and while these processes are essential for 
the normal functioning of mitochondria and the cell, this balance ultimately controls 
life and death signals (van der Bliek et al., 2013). While we (Sishi et al., 2013) and 
others (Parra et al., 2008) have been previously demonstrated that mitochondria 
present with an abnormal shape during DOX treatment; this study found it pertinent 
to evaluate mitochondrial morphology when DUBs were knocked-down in the 
absence and presence of DOX (Fig. 3.14). Normal mitochondria present themselves 
in various shapes and sizes including elongated, fragmented, rounded and 
intermediate (Rosca & Hoppel, 2010). Despite the various shapes and sizes, the 
majority of the mitochondria appeared interconnected and tubular in structure. When 
DOX was introduced, less mitochondria were observed; they were severely 
fragmented and rounded, and eventually lost their interconnectivity. While 
mitochondria seemed to gain their interconnectivity when each of the DUBs was 
knocked-down, some mitochondria remained fragmented and rounded, whereas 
others were intermediate in appearance. Overall, the down-regulation of DUBs 
resulted in ‘healthier looking’, mitochondria than DOX treated conditions alone. The 
most prominent feature observed when DUBs were knocked-down in the presence 
of DOX was their increased density (Fig. 3.15). Although different mitochondrial 
shapes were seen in a similar manner to the control, it is clear from these 
observations that USP down-regulation influences mitochondrial structure in a 
beneficial manner. 
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Figure 0.14: The effect of DUB (SiRNA) down-regulation on mitochondrial morphology in vitro 
DUB known-down was achieved by electroporation using SiRNA, where after H9C2 cardiomyoblasts 
were treated with 0.2 µM DOX daily for 120 hrs. Cells were stained with Hoechst (blue) to indicate 
nuclei and MitoTracker green to reveal mitochondrial networks. Abbreviations: DOX - Doxorubicin, KD 
– Knock-down, USP - Ubiquitin Specific Protease. Magnification = 60x, Scale bar = 20 µm 
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Figure 0.15: The effect of DUB (SiRNA) down-regulation in the presence of DOX on 
mitochondrial morphology in vitro. 
DUB known-down was achieved by electroporation using SiRNA, where after H9C2 cardiomyoblasts 
were treated with 0.2 µM DOX daily for 120 hrs. Cells were stained with Hoechst (blue) to indicate 
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nuclei and MitoTracker green to reveal mitochondrial networks. Abbreviations: DOX - Doxorubicin, KD 
– Knock-down, USP - Ubiquitin Specific Protease. Magnification = 60x, Scale bar = 20 µm 
3.4 Mitochondrial Health Assessment post SiRNA (down-regulation) of 
de-ubiquitinating enzymes in the presence of DOX 
With mitochondrial homeostasis being central to the present study, it became 
appropriate to determine mitochondrial health and efficiency. As mentioned 
previously, mitochondria are the energy producing organelles in cells via oxidative 
phosphorylation (Martinou & Youle, 2011). Due to the high energy demands of the 
heart and its need for a continuous supply of ATP (Rosca et al., 2008), cardiac cells 
have dense mitochondrial populations which make up ± 35% of their cellular volume 
(Hom & Sheu, 2009). 
Healthy functional mitochondria are essential for cell viability, and so mitochondrial 
toxicity was assessed by measuring dead cell protease activity present in the cytosol 
and released by mitochondria of dying cells (Suzuki et al., 2001; Niles et al., 2007). 
When DOX was introduced to the cells (Fig. 3.16), a significantly higher level of 
dead cell protease activity (151.3 ± 5.2%, p<0.01) was observed when compared to 
the control (100.0 ± 12.9%). While no significant changes were established when 
USP30 and USP36 were knocked-down in the presence of DOX versus the DOX 
treated group alone, even though a trend towards a decrease was observed, the 
knock-down of USP9x in the presence of DOX significantly reduced dead cell 
protease activity (113.2 ± 1.3%, p<0.05) suggesting a substantial improvement in 
mitochondrial health. What is also clear from the results is that the knock-down of 
these specific DUBs does not result in detrimental consequences for the 
mitochondria and cell as a whole. 
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Figure 0.16: The effect of DUB (SiRNA) down-regulation in the absence and presence of DOX 
on mitochondrial toxicity measured by dead cell protease activity. 
DUB known-down was achieved by electroporation using SiRNA, where after H9C2 cardiomyoblasts 
were treated with 0.2 µM DOX daily for 120 hrs. The relative fluorescent signal observed was 
evaluated. Results are represented as mean ± SEM (n = 3); **p<0.001 vs. Control, 
#
p<0.05 vs. DOX. 
Abbreviations: DOX - Doxorubicin, KD – knock-down, USP - Ubiquitin Specific Protease 
 
To complement the results obtained above, mitochondrial efficiency in the form of 
ATP production was measured and this was used as an indication of cell survival 
(Fig. 3.17). The damage that DOX induces to mitochondria was clearly reflected in 
this assay as ATP production was significantly reduced (41.5 ± 2.5%, p<0.01) when 
compared to the control (100.0 ± 14.6%). Interestingly, the general knock-down of 
USP36 (187.2 ± 9.9%, p<0.001) and USP9x (158.9 ± 14.3%, p<0.001) also 
produced significantly elevated levels of ATP versus the control and thereby 
suggests an important role for these DUBs in their down-regulated state. Moreover, 
the knock-down of USP30 (103.7 ± 8.0%, p<0.001), USP36 (114.1 ± 10.7%, 
p<0.001) and USP9x (86.8 ± 2.5%, p<0.05) in the presence of DOX caused a 
considerable increase in ATP production; however not to the same extend as without 
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DOX. It is thus clear from the results presented in this chapter that DOX is toxic to 
the mitochondria in these cells and this toxicity involves the active involvement of the 
UPS. Nevertheless, this study has now demonstrated from the above experiments, 
that by manipulating the expression of specific DUBs relevant in this context, this can 
be beneficial in improving mitochondrial morphology, reducing mitochondrial toxicity 
and increasing ATP production. 
 
 
Figure 0.17: The effect of DUB (SiRNA) down-regulation in the absence and presence of DOX 
on ATP production from mitochondria. 
DUB known-down was achieved by electroporation using SiRNA, where after H9C2 cardiomyoblasts 
were treated with 0.2 µM DOX daily for 120 hrs. The relative fluorescent signal observed was 
evaluated. Results are represented as mean ± SEM (n = 3); **p<0.01, ***p<0.001 vs. Control; 
#
p<0.05, 
###
p<0.001 vs. DOX. Abbreviations: DOX - Doxorubicin, KD – knock-down, USP - Ubiquitin 
Specific Protease 
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DISCUSSION 
 
As cancer outcomes advance, cardiovascular disease has become the primary 
cause of morbidity and mortality among cancer survivors; and the foundation of this 
cancer-related cardiomyopathy is chemotherapy. Targeted anti-cancer and cytotoxic 
drugs such as anthracyclines can progress to HF particularly in patients with pre-
existing heart disease, childhood cancer survivors and the elderly (Van Dalen et al., 
2007). While oxidative stress was previously indicated as the major role player 
(Minotti et al., 2004), mitochondrial dysfunction has since become a noticeable trait 
of DOX-induced cardiotoxicity (Green & Leeuwenburgh, 2002). Mitochondrial 
function is regulated by the dynamic processes of fission and fusion (known as 
mitochondrial dynamics); and prior work by our group demonstrated that during DOX 
treatment mitochondrial fission is favoured over fusion (Opperman, 2015). The fine 
balance of mitochondrial dynamics is in part regulated by the UPS and this 
mechanism is reversible with the use of DUBs (Endo et al., 2009; Youle et al., 2011). 
This study therefore hypothesized that by manipulating the presence of specific 
DUBS relevant in this context, this would enhance mitochondrial health, increase 
ATP synthesis and overall cellular survival. 
 
4.1 DOX induces apoptosis by increasing USP9x 
Apoptosis is a known mechanism by which DOX destroys both cancer cells and 
cardiomyocytes. Direct DNA intercalation is the favoured method for highly 
proliferative cells (Berthiaume and Wallace, 2007), while indirectly oxidative stress 
and mitochondrial damage impairs myocardial cells (Minotti et al., 2004; Green & 
Leeuwenburgh, 2002). Although oxidative stress may also contribute to DOX-
induced apoptosis in cancer, cardiac cells are especially susceptible to the damaging 
effects of oxidative stress due to their lower levels of anti-oxidant defences 
(Doroshow et al., 1980, James Kang et al., 1996). 
MCL-1 is a member of the Bcl-2 family of apoptosis regulating proteins. With various 
functions including the development and maintenance of B and T lymphocytes 
(Opferman et al., 2003) and cell cycle progression (Fujise et al., 2000), the most 
significant function in this context is its regulatory role in apoptosis. MCL-1 can 
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undergo post-transcriptional and translational modification to form, a long anti-
apoptotic (MCL-1L) and a short pro-apoptotic fragment (MCL-1S) (Bae et al., 2000; 
Thomas et al., 2010). MCL-1L binds and sequesters Bak, Bax and other pro-
apoptotic BH3-only proteins of the Bcl-2 family including MCL-1S. This prevents 
these proteins from forming pores within the mitochondrial membrane, causing the 
release of cytochrome c via the mitochondrial permeability transition pore (mPTP), 
and downstream caspase activation (Bae et al., 2000). Its variant, MCL-1S is a BH3-
only protein, and functions as a ligand which can dimerize with MCL-1L on the 
mitochondrial membrane. There it induces apoptosis through the activation of 
downstream caspases and as such acts in an antagonistic manner to MCL-1L. Our 
results clearly demonstrate that DOX stimulates apoptosis by decreasing the 
expression of anti-apoptotic MCL-1L (Fig. 3.2) whilst increasing the pro-apoptotic 
MCL-1S (Fig. 3.3) in vitro and in vivo. According to a review by Karbowski et al., 
(2011), USP9x is one of only two mitochondrial associated DUBs that have been 
identified at present (Schwickart et al., 2010). This enzyme de-ubiquitinates and 
stabilizes MCL-1 which is targeted for degradation by MULE (MCL-1 ubiquitin 
ligase). We found that during cytotoxicity and cardiotoxicity, USP9x was substantially 
elevated (Fig. 3.1). This increase possibly suggests that USP9x removes ubiquitin 
molecules tagged to MCL-1 to prevent its degradation. Since MCL-1 has two 
fragments, pro-apoptotic MCL-1S is preserved rather than the anti-apoptotic MCL-
1L. In doing so, apoptosis is induced. As there are no effective treatment strategies 
for DOX-induced toxicity, exploiting USP9x function may be way in which apoptosis 
can be reduced. 
 
4.2 DOX treatment promotes mitochondrial fission by reducing USP30 
Changes in mitochondrial morphology are a typical response to mitochondrial stress 
stimuli (Barbour & Turner, 2014). These changes in morphology are regulated by 
mitochondrial membrane proteins which govern mitochondrial dynamics. Parra et al., 
(2008) illustrated that mitochondrial stress which culminates in cardiomyocyte 
apoptosis is in fact preceded by extensive mitochondrial fragmentation. As 
mentioned previously, mitochondrial fission machinery involves the proteins Drp1 
and Fis1 which are subsequently ubiquitinated by the E3 ligase MITOL (MARCH5), 
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which compromises their fission promoting function (Nakamura et al., 2006; 
Karbowski et al., 2007; Yonashiro et al., 2006); whereas mitochondrial fusion 
machinery involves MFN 1/2 and OPA1, and are tagged for degradation by the E3 
ligase Parkin (Tanaka et al., 2010; Gegg et al., 2010). The other DUB that has been 
identified is USP30, however its mitochondrial substrates remain to be conclusively 
elucidated (Nakamura et al., 2008; Karbowski et al., 2011). It is thus probable that 
USP30 facilitates de-ubiquitination of certain mitochondrial proteins involved in 
mitochondrial dynamics, as down-regulation of this DUB by RNAi is said to promote 
elongated mitochondrial networks which is indicative of fusion and inhibits mitophagy 
(Nakamura et al., 2008; Bingol et al., 2014; Yue et al., 2014). The current study has 
since demonstrated that USP30 is severely reduced in the presence of DOX in vitro 
(Figs. 3.4 & 3.9) and in vivo (Fig. 3.4). This suggests that the mitochondrial proteins 
that are meant to be de-ubiquitinated by USP30 are tagged with ubiquitin molecules 
that signal for their degradation by the proteasome. We also noted that USP30 is not 
only localized to the peri-nuclear region (possibly mitochondria) as observed in 
literature (Nakamura & Hirose, 2008; Bingol et al., 2014).  We were also able to 
detect some localization within the nucleus specifically in the control cells. Little has 
been reported on this in literature, but it could be also observed in the results 
obtained by Bingol et al., (2014). Nakamura & Hirose, (2008), also observed non-
mitochondrial targeting of a mutant USP30 type. This, in addition to our findings 
could suggest a nuclear based function of USP30 subtypes in control cells, which is 
eliminated in the presence of DOX. USP30 localization is dependent on the net 
charge in its C-terminal transmembrane span and flanking region (Nakamura & 
Hirose, 2008), and DOX has been established to be positively charged 
(Goormaghtigh et al., 1980). This interaction could influence USP30 localization. 
Based on the above, our findings are in agreement with some studies that proved 
that USP30 does indeed associate with MFNs (Bingol et al., 2014; Yue et al., 2014). 
Numerous studies have established that modifications in mitochondrial morphology, 
due to an imbalance between fission and fusion events within the myocardium, 
mediate the pathophysiology of HF (Kuzmicic et al., 2011; Marín-García et al., 2013). 
Furthermore, literature reveals that elevated ROS production and oxidative stress, a 
known side effect of DOX treatment, mediates mitochondrial fission (Dagda et al., 
2009; Frank et al., 2012). These findings lead to the theory that dysregulation of 
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mitochondrial dynamics is associated with DOX-induced cardiotoxicity. The 
importance of MFN1 and MFN2 in maintaining normal mitochondrial morphology and 
function has been highlighted in elegant knock-out models. Whereas Papanicolaou 
et al., (2012) showed that double knock-out of both MFNs in mice caused the 
accumulation of aberrant mitochondria in cardiomyocytes, Chen and colleagues 
(2011) demonstrated that cardiac specific deletion of either MFN1 or MFN2 triggers 
mitochondrial dysfunction and lethal dilated cardiomyopathy. Therefore, from the 
above studies, it can be deduced that obstruction of either of these fusion proteins 
can have detrimental consequences for the myocardium. Based on our data MFN1 
was significantly reduced in both models (Fig. 3.5) and MFN2 was augmented in 
vitro (Fig. 3.6), which was in contrast to our previous results (Opperman, 2015). As 
USP30 and MFN1 were both down-regulated in both models, it may imply that MFN1 
was degraded or its synthesis was inhibited since there was no inhibitory protein 
(absence of USP30) that would prevent its degradation. Additionally, these results 
point toward the notion that USP30 is certainly a specific DUB for MFN1 and this is a 
novel finding in this context. 
Interestingly, this phenomenon was not realised when considering MFN2, which is 
arguably the more influential fusion protein, as loss of this protein alone was 
demonstrated to significantly impair mitochondrial fusion (Ni et al., 2014). The 
increase in protein expression of MFN2 observed in this study may either indicate a 
compensatory response due to loss of MFN1, or that USP30 does not prevent 
degradation of MFN2 as indicated earlier by others (Bingol et al., 2014; Yue et al., 
2014). Moreover, if USP30 has an effect on MFN2, it is likely involved in the 
regulation of this fusion protein via Lysine-63 (Lys-63) associated ubiquitination 
rather than Lysine-48 (Lys-48). Lys-63 ubiquitination regulates function and 
localization of proteins whereas Lys-48 causes degradation (Wilkinson, 2009). It thus 
becomes apparent that although the mechanism by which DOX causes USP30 
down-regulation remains to be elucidated, our results dictate the influential role that 
USP30 plays in this context. 
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4.3 SOD2 is elevated in response to DOX-induced oxidative stress 
The central player suggested to be part and parcel of DOX cardiotoxicity is oxidative 
stress generated during intracellular metabolism (Vander Heide et al., 2007; 
Schimmel et al., 2004). This idea has been pivotal in the argument that since adult 
cardiomyocytes are terminally differentiated cells that are highly susceptible to 
oxidative stress as a result of their high oxidative metabolism, oxidative damage to 
the myocardium can lead to irreversible injury depending on its severity. For 
example; mild oxidative stress is said to trigger mitophagy either to promote survival 
or induce death. Secondly, moderate oxidative stress encourages apoptotic cell 
death following mitochondrial membrane permeabilization and the liberation of 
cytochrome-c. This is true considering that ROS can accumulate within mitochondria 
to generate more ROS and oxidatively damaged mitochondria can also produce 
even more ROS (Suzuki et al., 2001). This creates a vicious cycle that is destructive. 
Finally, severe oxidative stress brings about necrosis owing to ATP exhaustion (Pan 
et al., 2009). 
As such, in vitro experiments utilising cardiomyocytes propose that anti-oxidants 
such as α-phenyl-tert-butyl nitrone, 5-aminosalicyclic acid, trolox or aminofostine, 
administered prior to DOX treatment, decreases oxidative stress and myocyte injury 
(DeAtley et al., 1999; Dorr et al., 1996). In vivo, transgenic mice over-expressing 
SOD and catalase, major intracellular anti-oxidants, have been demonstrated to be 
cardio-protective (Kang et al., 1996; Yen et al., 1996). Interestingly it was found that 
the level of catalase activity in the heart to produce these beneficial effects were 
between 60-100 fold higher than normal. It is however unlikely that this can be 
achieved with the current strategies; and mechanisms to constantly maintain these 
elevated levels are non-existent at present. The failure of this strategy clinically (Van 
Dalen et al., 2008), and the disagreement in literature regarding the most favourable 
treatment regime has resulted in this study taking a different approach by 
investigating the role that DUBs play in this context. SOD2 (MnSOD) is ubiquitinated 
by MARCH5 (MITOL) (Yonashiro et al., 2006; Yonashiro et al., 2009) for degradation 
and Kim et al., (2011) proposed that the non-mitochondrial DUB, USP36, localized to 
the nucleoli is vital for reducing the ubiquitination levels of SOD2 in a cancer cell line. 
Disappointingly, our western blot data showed no noteworthy changes in either of 
our models (Fig. 3.7), however, when we stained for USP36 in vitro (Fig. 3.10), a 
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different picture emerged. USP36 expression was detected within the nucleus under 
normal conditions which corroborates the study cited above (Endo et al., 2009; Kim 
et al., 2011). In contrast to the observations above, DOX amplified USP36 
fluorescent signal and this localisation emerged outside and around the nucleus as 
protein aggregates. The significance of forming aggregates in this context is 
unknown. If we consider these results, it could possibly indicate that due to DOX-
induced oxidative stress, the cells would naturally respond by increasing their anti-
oxidant defences. In this case SOD2 was significantly up-regulated in vitro (Fig. 3.8) 
while no changes were seen in vivo. This suggests that the extra-nucleolar 
expression of USP36 in the presence of DOX counteracted SOD2 Lys-48 
ubiquitination and prevented its degradation. In this context, these results are 
considered to be beneficial seeing that DOX is known to induce oxidative stress 
(Minotti et al., 2004).  
In light of the above results, this study has now illustrated that DOX treatment has a 
strong influence on the presence and/or absence of specific DUBs relevant in this 
scenario and this influences down-stream substrates that mediate apoptotic cell 
death, mitochondrial function and ROS scavenging. To further elaborate on these 
experiments and to determine the functional significance of these DUBs in this 
context, down-regulation was attempted to not only ascertain what happens to the 
down-stream targets, but also mitochondrial health and ATP synthesis. 
 
4.4 USP9x down-regulation reduces MCL-1S during DOX treatment 
It has previously been reported that the knock-down of USP9x sensitizes cells to 
cytotoxic stimuli that results in cell death via MCL-1 dependent mechanisms 
(Schwickart et al., 2010). When USP9x (Fig. 3.11A) was knocked-down in this 
setting, the pro-apoptotic short-fragment MCL-1S (Fig. 3.11C) was reduced while the 
anti-apoptotic long-fragment MCL-1L (Fig. 3.11B) was modestly elevated versus the 
DOX alone group. This was in line with our baseline results already discussed above 
and validates our previous suggestion that USP9x preserves MCL-1S from 
degradation rather MCL-1L. A noteworthy observation was the fact that USP9x 
down-regulation alone was also associated with higher expression of both MCL-1 
fragments when compared to the control, however; when DOX was administered, 
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MCL-1L appeared to be more sensitive to this stressor than MCL-1S suggesting an 
inhibitory effect in MCL-1L activity in the presence of DOX. An interesting oversight 
by current literature with regards to the relationship between USP9x and MCL-1 is 
the lack of information regarding the specificity of the interaction between USP9x 
and the MCL-1 fragments. Current literature has taken a one-dimensional approach 
towards investigating the relationship between these proteins, and this makes the 
differential relationship between USP9x and the two MCL-1 fragments observed by 
this study an interesting one. Our results suggest that USP9x is a more specific de-
ubiquitinase for MCL-1S, and this could be due to the structural differences between 
MCL-1S and MCL-1L observed by Bae et al., (2000). Against expectations, down-
regulating USP9x alone was not sufficient to reduce MCL-1S expression, but this 
down-regulation in combination with DOX treatment reduced MCL-1S expression 
compared to DOX only groups and even showed a trend towards reduced 
expression compared to the control group (Fig 3.11). This goes to suggest that in the 
presence of the toxic insult by DOX, and the increase in USP9x expression induced 
by DOX treatment, MCL-1S expression increases due to increased de-ubiquitination 
by USP9x. However, when USP9x is downregulated within this context, increased 
ubiquitination of MCL-1S by MULE occurs, and with less USP9x present, the 
increase in MCL-1S caused by DOX induced USP9x up-regulation, is inhibited, and 
so MCL-1S gets degraded by the UPS.  
Overall, the knock-down of USP9x in the presence of DOX can be viewed as 
favourable due to an increase in anti-apoptotic and a decrease in pro-apoptotic 
signals. 
 
4.5 USP30 down-regulation increases MFN2 and decreases MFN1 in the 
presence of DOX 
USP30 has been reported to de-ubiquitinate Parkin’s substrates within the 
mitochondria. Parkin has been identified as the likely E3 ligase which tags MFN 
proteins with ubiquitin molecules for Lys-48 associated proteasomal degradation 
(Liang et al., 2015). As such, USP30 is believed to de-ubiquitinate MFN proteins to 
preserve their function. This study was able to show that USP30 has differential 
effects on MFN1 (Fig. 3.12B) and MFN2 (Fig. 3.12C). Our initial baseline data 
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showed that pro-longed DOX treatment was accompanied by a reduction in MFN1 
(in vitro and in vivo) possibly due to the decrease in USP30, which indicates that 
MFN1 degradation is linked to the absence of USP30. This further implies that 
USP30 does in fact de-ubiquitinate MFN1 to prevent its degradation in this setting. 
This was confirmed by USP30 knock-down, which caused an additional decrease in 
MFN1 expression alone and when DOX was administered. While USP30 has been 
determined to de-ubiquitinate mitochondrial proteins (Karbowski & Youle, 2011; 
Bingol et al., 2014), literature has not yet pin-pointed the exact relationship between 
USP30 and the mitofusins, however Nakamura & Hirose, (2008) were able to 
determine that down-regulation of USP30 induced mitochondrial network elongation, 
indicative of increased mitochondrial fusion. And while the reduction in MFN1 
expression due to USP30 down-regulation contradicts these findings, the response 
of MFN2 to USP30 knockdown could explain their results.  
MFN2 was increased during chronic DOX treatment alongside reduced USP30 
expression. By knocking-down USP30 in absence and presence of DOX, this lead to 
an even greater expression of MFN2 when compared the control and DOX groups 
respectively. This may either indicate a compensatory mechanism between the two 
MFN proteins as they both regulate mitochondrial fusion or that USP30 is not 
responsible for the anti-degradative de-ubiquitination of MFN2. While literature is yet 
to elucidate in detail the relationship between the mitofusins and USP30, Liang et al., 
(2015) indicate that both mitofusins are de-ubiquitinated by USP30 and this brings 
into the focus the different types of ubiquitination. We postulate that USP30 cleaves 
ubiquitin molecules bound to MFN2, however, it is more specific for lysine-63 
regulatory ubiquitin bonds, a suggestion which is backed up by Anton et al., (2013) 
report that mitofusins are ubiquitinated on two conserved lysine residues. Down-
regulating USP30 in this context could enable more Lys-63 linked ubiquitination, 
which could lead to regulation of its activity and function, and also stimulating an 
increase in MFN2 transcription. This is beneficial in this context, as increased MFN2 
levels would help reduce the level of mitochondrial fragmentation induced by DOX 
treatment even more so than the compensatory increase caused by DOX. 
USP30 down-regulation would also lead to an increase in parkin-mediated 
mitophagy (Bingol et al., 2014). Bingol et al., (2014) reported that over-expression of 
USP30 led to reduced mitophagy as USP30 removes ubiquitin molecules attached to 
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mitochondria by parkin. As such, reduced USP30 expression would be accompanied 
by an increase in mitophagy. This would be beneficial in this context, as this 
increased mitophagy would enable degradation of mitochondria irreversibly 
damaged by DOX, while the concurrent increase in MFN2 expression would enable 
reintegration of viable mitochondria into the mitochondrial network.   
 
4.6 USP36 down-regulation improves mitochondrial anti-oxidant expression 
post chronic DOX treatment 
This study showed that chronic DOX treatment did not induce any changes in 
USP36 expression. We were also able to show that chronic DOX treatment induced 
a compensatory increase in SOD2 expression in vitro. This seemed to imply that our 
earlier belief that USP36 expression is directly linked to SOD2 expression may not 
be completely accurate as SOD2 was increased significantly, without a 
corresponding increase in USP36 expression. Down-regulating USP36 did not lead 
to any significant changes in SOD2 expression. This indicated that an absence of 
USP36 did not lead to increased level of SOD2 degradation by the UPS. When 
USP36 knock down cells were subjected to chronic DOX treatment however, there 
was a markedly increased expression of SOD2, showing that down-regulating 
USP36 escalated the compensatory increase in SOD2 expression induced by 
chronic DOX treatment. The mechanisms through which this occurs are still unclear, 
however, Kim et al., (2011), reported that USP36 regulated SOD2 stability by 
removing poly-ubiquitin chains and improving the half-life of SOD2 and that would 
imply that down-regulating USP36 would increase SOD2 turnover. This could explain 
the increased SOD2 expression in DOX treated USP36 knock down cells, as this 
increased turnover could also induce increased transcription which would be 
protective in the context of DOX-induced cardiotoxicity.  
 
DUB down-regulation influences mitochondrial morphology, improves toxicity 
and efficiency in the context of chronic DOX induced cardiotoxicity  
Mitochondrial morphology is an important indicator of cellular health. Exposure to 
acute and chronic insults within the myocardium modifies mitochondrial morphology 
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depending on the severity of the insult (Ho & Duffield., 2000). Excessive 
mitochondrial fragmentation is generally considered a sign of stress and is harmful to 
cellular homeostasis. It has been associated with increased levels of apoptosis 
(James et al., 2003) and oxidative stress (Sciaretta et al., 2014; Ikeda et al., 2015) 
and this phenomenon has been observed in a number of disease states including 
diabetes, liver diseases, ageing and cancer (Wallace, 1999), suggesting a critical 
role of mitochondrial morphology in the context of these diseases. 
In the context of DOX toxicity, we have previously indicated that mitochondria appear 
as short, rounded and fragmented organelles that display no interconnectivity with 
one another. Furthermore, these mitochondria were found to have decreased 
membrane potential and resulted in apoptotic cell death possibly due to extensive 
mitochondrial damage and cytochrome-c leakage (Sishi et al., 2013). While the study 
cited was conducted in an acute setting (3 µM DOX for 24 hrs), the results presented 
in the current study were similar albeit a chronic setting was utilised (Fig. 3.14). This 
implies that irrespective of duration or concentration, DOX induces abnormal 
mitochondrial changes to the mitochondria that influence cellular death. This may be 
due to DOX’s affinity for cardiolipin and DOX-induced oxidative stress 
(Goormaghtigh et al., 1980). When DOX binds to cardiolipin forming a steady 
complex, it renders cardiolipin inept in its role as a co-factor for various mitochondrial 
respiratory proteins thus preventing oxidative phosphorylation and reducing ATP 
(Goormaghtigh & Ruysschaert, 1984; Goormaghtigh et al., 1986). Additionally, when 
DOX’s lipophilic metabolite (7-deoxyaglycone) accumulates within the inner 
mitochondrial membrane where cardiolipin resides, electrons are redirected to 
oxygen to form free radicals instead. These events culminate in increased 
mitochondrial permeability, oxidation of NADH, mitochondrial swelling and ultimately 
mitochondrial dysfunction (Doroshow, 1983). 
To maintain cell survival, mitochondria present themselves in different shapes and 
sizes, as they are constantly undergoing fission and fusion processes. However, 
most mitochondria are extended, tubular in shape and present themselves with a 
high degree of interconnectivity. When this study down-regulated the DUBs alone, 
more mitochondria were present with improved appearance and a great degree of 
branching. Surprisingly, even after DOX was added (Fig. 3.15), mitochondrial were 
able to maintain their shape despite some degree of damage. Bingol et al., (2014) 
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demonstrated that USP30 opposes parkin-mediated mitophagy, and as such USP30 
knock-down showed less dense mitochondrial networks compared to the control 
suggesting an increase in mitophagy induced by USP30 down-regulation. Bach et 
al., (2003) also demonstrated that MFN2 played a significant role in the regulation of 
mitochondrial networks and mitochondrial efficiency. The increase in MFN2 
expression in the presence and absence of DOX could be responsible for the 
increased mitochondrial fusion observed when USP30 was down-regulated. This 
may indicate that USP30 knock-down was protective of mitochondrial network state 
within the context of chronic DOX toxicity. USP9x knock-down showed rounded 
mitochondria symptomatic of fragmentation, however, these cells showed a high 
mitochondrial density compared to both control groups. DOX treated USP9x (SiRNA) 
cells displayed similar mitochondrial network morphology, showing that down-
regulating USP9x led to fragmented mitochondria, but was protective against the 
extensive fragmentation and mitochondrial degradation observed in DOX control 
cells. Morciano et al., (2016) reported that a high MCL-1S/MCL-1L ratio results in 
significant hyperfusion of the mitochondrial network. This hyperfusion is reportedly 
dependent on DRP1, and sensitizes cells to apoptosis. Down-regulating USP9x led 
to a reduction in the MCL-1S/MCL-1L ratio, leading to fragmented but denser 
mitochondrial networks that could be more resistant to apoptotic stimuli within this 
context. USP36 down-regulation alone did not seem to influence mitochondrial 
network morphology extensively in terms of density and fragmentation compared to 
the control, but USP36 knockdown in the presence of DOX, extensively increased 
mitochondrial network fusion and density compared to DOX controls. This indicates 
that the significant increase in SOD2 induced by down-regulating USP36 in the 
presence of DOX is protective in this context, as it helped restore mitochondrial 
network morphology.  
Down-regulating these DUBs was also protective in other mitochondrial parameters, 
as we were able to determine that down-regulating USP9x helped reduce overall 
mitochondrial toxicity compared to DOX controls (Fig. 3.16). Fragmentation in this 
context induced by USP9x, seemed to be protective so long as mitochondrial 
network density remained healthy. This could be an avenue for further exploration 
considering that mitochondrial density as well as the levels of mitophagy, and not 
just mitochondrial morphology could be more significant in the aetiology of 
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cardiomyopathies associated with DOX induced toxicity. As expected, chronic DOX 
treatment led to an inhibition of cellular ATP synthesis however, by down-regulating 
each of the three DUBs, this seemed to enhance mitochondrial efficiency compared 
to DOX controls (Fig. 3.17). The exact mechanism by which this happens remains 
unknown but the present data seem to indicate that by down-regulating both USP30 
and USP36 help maintain mitochondrial health by reducing of mitochondrial 
fragmentation and DOX-induced mitophagy through elevated MFN2 and SOD2 
respectively. USP9x increased mitochondrial network density, and while there was 
no visible reduction in mitochondrial fragmentation, the reduction in the MCL-
1S/MCL-1L ratio helped reduce the pro-apoptotic stimuli exerted by the chronic DOX 
treatment. These mechanisms lead to increased mitochondrial health, and improved 
cellular ATP synthesis, which was compromised by DOX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
67 
 
CONCLUSION 
 
In the race against time to find sustainable solutions to the problems associated with 
chemotherapy, DOX-induced cardio(cyto)toxicity is a huge stumbling block to any 
reasonable progress made thus far. The chronic form of this condition has made it 
even more difficult to curb with lower doses of DOX still leading to the progression of 
HF over period of time. The mechanism by which the chronic form of this disease 
leads to cardiomyopathy is related to not only oxidative stress, but mitochondrial 
dysfunction due to possible dysregulation of the UPS, a major protein quality control 
mechanism in a cell. The UPS plays a pivotal role in the regulation of mitochondrial 
efficiency, morphology, targeted degradation via mitophagy and apoptosis. Since the 
process of ubiquitination is reversible due to the presence of DUBs, this study 
explored their potential role in this context.  
Considering that mitochondria are highly abundant in the myocardium due to the 
metabolic demands of this organ, their health and function needs to be maintained at 
all times. However due to DOX having such a high affinity for mitochondria, it 
stimulates detrimental changes to these organelles ultimately resulting in their 
dysfunction. Oxidative stress, abnormal mitochondrial morphology, apoptosis and 
reduced ATP synthesis are all critical role players in the development of chronic 
DOX cardiotoxicity and its advancement to HF, and this study showed that DUBs are 
influential in the modulation of these processes. DOX itself induces differential 
protein expression of specific DUBs assessed in study and in doing so, promotes 
fragmented mitochondria and consequently oxidative stress, reduced ATP synthesis 
and apoptotic cell death by reducing USP30 and USP36 and by elevating USP9x 
respectively. Therefore, by down-regulating each of the DUBs by using SiRNA, we 
demonstrated improved mitochondrial morphology and MnSOD expression, reduced 
mitochondrial toxicity and pro-apoptotic signalling, and finally enhanced ATP 
production. These effects are extremely beneficial to the heart to maintain optimum 
cellular and organelle function. By demonstrating a role for DUBs in this context and 
exploiting their down-stream effects in their absence, and in the absence and 
presence of DOX, this study has opened a potential avenue of exploitation for 
targeted treatment for cardiotoxicity during DOX treatment.  
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An obvious limitation of this study was the fact that only one half of the puzzle was 
investigated. The roles of these DUBs within the context of chronic DOX-induced 
cardiotoxicity cannot be fully elucidated until the effect of up-regulating these and 
their down-stream effects assessed. While this study did attempt to up-regulate 
these specific DUBs, our trials were unsuccessful due to the low transfection 
efficiency of the cell line used. A more suitable approach for this cell line would be to 
use CRISPR technology, however due to limited funds we were not able to utilise 
this technique.  
Other potential avenues that should be explored include the differential effect that 
DOX has on MFN1 and MFN2. In this current study, MFN1 was reduced, whereas 
MFN2 was elevated in the presence of DOX while UPS30 was down-regulated. It is 
thus tempting to speculate that should USP30 be increased, MFN1 is expected to 
increase and MFN2 to decrease in the presence of DOX. This would then confirm 
that indeed USP30 de-ubiquitinates both MFNs and not only MFN1 as indicated by 
the results in this study within this particular context. Interestingly, MFN2 has 
previously been demonstrated to function as one of the proteins involved in tethering 
mitochondria to the SR in areas known as mitochondrial-ER associated membranes 
(MAMs) (de Brito & Scorrano, 2008). MAMs influence a number of SR-linked 
mitochondrial regulatory processes, including calcium regulation. Calcium regulation 
is especially important in the excitation/contraction coupling of the myocardium and 
modifications in this process will affect proper function of the heart. Furthermore, 
calcium is involved in the activation of calpains, the initiation of apoptosis and 
necrosis, and mitochondrial fragmentation (Nakagawa et al., 2000; Marongiu et al., 
2009).  
With all things considered, the findings presented in this study go a long way in 
expanding the scientific knowledge related to cardiotoxicity and the field of cardio-
oncology. These findings in addition to potential therapeutic effects are of immense 
benefit to not only the scientific community at large but also to the numerous cancer 
survivors world-wide. 
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APPENDICES 
Appendix A 
Supplementary Results 
Immunocytochemistry on Mitofusin proteins 
MFN1 
As indicated in Fig. A.1, MFN1 was highly expressed under control conditions, 
whereas daily treatment with DOX caused a significant reduction in the fluorescent 
signal of this mitochondrial fusion protein. These observations imitate those obtained 
by western blotting (Fig. 3.5). Upon further scrutiny, MFN1 not only localized around 
the nucleus but also within the nucleus (control). These proteins appeared as large 
prominent aggregates within these regions of localization. While some aggregation 
was noticed during treatment with DOX, these were not as large, nor as prominent. 
 
Figure A. 1: Immunofluorescent images showing relative protein expression of MFN1 during 
untreated and treated conditions with DOX in vitro. 
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H9C2 cardiomyoblasts were treated with 0.2 µM DOX daily for 120 hrs (Blue - nucleus, Green – 
MFN1). Peri-nuclear localisation is indicated by arrows (yellow) and localisation within the nuclear 
region is indicated by circles (white). Abbreviations: DOX – Doxorubicin, MFN1 – Mitofusin 1. 
Magnification = 40x, Scale bar = 25 µm. 
MFN2 
The second mitofusin (MFN2) influenced by USP30 was also assessed by 
fluorescent microscopy; and while not as conclusive, a rather faint fluorescent signal 
was observed in the control group and even less in the DOX group as shown in the 
images below (Fig. A.2). The increased protein expression of MFN2 seen in Fig. 3.6 
during DOX treatment thus does not complement the fluorescent signal observed in 
this experiment. Considering that both techniques used to detect USP30 and MFN1 
produced substantially decreased results in the presence of DOX, this may suggest 
that USP30 targets MFN2 rather than MFN1 for de-ubiquitination to prevent its 
degradation, while MFN1 undergoes proteolysis. 
 
Figure A. 2: Immunofluorescent images showing relative protein expression of MFN2 during 
untreated and treated conditions with DOX in vitro. 
Stellenbosch University  https://scholar.sun.ac.za
82 
 
H9C2 cardiomyoblasts were treated with 0.2 µM DOX daily for 120 hrs (Blue - nucleus, Green – 
MFN2). Peri-nuclear localisation is indicated by arrows (yellow) and localisation within the nuclear 
region is indicated by circles (white). Abbreviations: DOX – Doxorubicin, MFN2 – Mitofusin 2. 
Magnification = 10x, Scale bar = 100 µm. 
Total protein stain free blot images  
 
A.3 A.4 
A.5 A.6 
A.7 A.8 
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Figure A. 3 - A. 15: Stain-free images showing total protein on the membranes used in blotting 
H9C2 cells and Sprague-Dawley rat tissue. 
A.9 A.10 
A.11 A.12 
A.13 A.14 
A.15 
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Appendix B 
Protocols 
Protocol 1: Cell culture 
 Cell Culturing 
o Make sure Lab coat is worn, wash hands, wear gloves, and then wash 
gloved hands. 
o Spray gloved hands with 70% ethanol, spray and wipe down laminar 
flow hoods, waste beakers, pipettes and all tubes placed in hoods with 
70% ethanol. 
o Make up DMEM media 
 Get 500ml DMEM media bottle and place in shaking incubator 
for an hour.  
 Place FBS and antibiotics in bead bath for 15 minutes.  
 Spray all with 70% ethanol and place in laminar flow hood, spray 
gloved hands as well. 
 Extract 55ml of DMEM from its stock bottle using a pipette and 
put into a labelled tube.  
 Add 55ml of FBS and 5ml of antibiotic to the stock DMEM bottle.  
 Swirl, shake or tilt gently and pipette into falcon tubes.  
 Seal falcon tubes with parafilm and place in fridge.  
o Cracking a vile  
 Get an appropriate vile from the liquid nitrogen canisters 
adhering to safety rules, and thaw at 37⁰ C.  
 Add 5ml of growth media to a T25 flask. 
 Pipette 1ml of the cells into the T25 flask, close cap, and swirl 
gently in a North-South-East-West manner.  
 Incubate at 37⁰ C and 5% CO2 until cells are 80% confluent.  
o Cell growth maintenance 
 Remove cells from incubator, and examine for confluence and 
health under microscope.  
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 If cells aren’t confluent but growing and healthy, replace media 
every couple days and re-incubate, while checking for health 
and confluence regularly.  
 Once cells are about 80% confluent, split cells.  
o Splitting cells 
 Place growth media, PBS and trypsin in bead bath for about 15 
minutes. 
 Discard old growth media, and gently wash with warm sterile 
PBS.  
 Add 4ml of trypsin to T25 and place in 37⁰ C shaking incubator 
for approximately 4-5 minutes to detach cells from bottom of 
flask.  
 Check for detachment from 3rd minute, and once detached and 
loose, add growth media double the amount of trypsin that was 
added to the flask to neutralize trypsin.  
 Transfer all flask content to a sterile falcon tube, and centrifuge 
at 1500 rpm for 3 minutes.  
 Carefully remove and dispose of supernatant once cells have 
formed pellet at the bottom.  
 Re-suspend pellet in 2ml of growth media for T25 flasks, and 
4ml for T75 flasks.  
 Count cells if seeding is to be done, or Pipette 1ml each into 
sterile T75 flasks. 
Protocol 2: Cell counting and seeding 
 Counting cells 
 After step F-vii above, wipe down haemocytometer with 70% ethanol,  
 Moisten haemocytometer surface with a brief breath, then add cover 
slip.  
 Gently pipette 20µL of re-suspended cells under the cover slip covering 
each chamber of the haemocytometer, and avoid bubbles.  
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 Count the number of cells in 3 boxes in a diagonal manner on the top 
haemocytometer grid under a microscope, and do the same for bottom 
grid 
  
Figure B. 1: Haemocytometer grid 
 Each block is 0.1µL 
 Calculate average of cells per block  
 
𝑇𝑜𝑝 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡+𝑏𝑜𝑡𝑡𝑜𝑚 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
6
 = number of cells in 0.1µl 
𝑎𝑛𝑠𝑤𝑒𝑟 × 10000 = 𝑛𝑜 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 1𝑚𝑙 
𝑛𝑜 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 1𝑚𝑙 × 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛
= 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡. 𝑣𝑜𝑙 ↔ 𝑡. 𝑣𝑜𝑙𝑢𝑚𝑒
𝐶𝑒𝑙𝑙𝑠 𝑡𝑜 𝑏𝑒 𝑠𝑒𝑒𝑑𝑒𝑑 ↔ 𝑥 𝑣𝑜𝑙𝑢𝑚𝑒 𝑚𝑙?
 
#cells to be seeded determined earlier depending on cell type, number 
of wells and treatment type.  
 
 
𝑥𝑚𝑙
1000
= 𝑥 µ𝑙 
𝑥µ𝐿 × 𝑛𝑜 𝑜𝑓 𝑤𝑒𝑙𝑙𝑠 (𝑦) = 𝑥𝑦 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 𝑡𝑜 𝑏𝑒 𝑝𝑖𝑝𝑒𝑡𝑡𝑒𝑑  
𝐺𝑟𝑜𝑤𝑡ℎ 𝑚𝑒𝑑𝑖𝑎 𝑡𝑜 𝑏𝑒 𝑢𝑠𝑒𝑑 𝑤𝑖𝑡ℎ 𝑑𝑟𝑢𝑔𝑠 (𝑚𝑙) × 𝑛𝑜 𝑜𝑓 𝑤𝑒𝑙𝑙𝑠
= 𝑧 𝑡𝑜𝑡𝑎𝑙 𝑚𝑒𝑑𝑖𝑎 𝑛𝑒𝑒𝑑𝑒𝑑 
𝑧 𝑡𝑜𝑡𝑎𝑙 𝑚𝑒𝑑𝑖𝑎 𝑛𝑒𝑒𝑑𝑒𝑑 − 𝑥𝑦 𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 = 𝑤 𝑚𝑒𝑑𝑖𝑎 𝑎𝑑𝑑𝑒𝑑 𝑚𝑙   
 Adapted from: 
http://www.hausserscienti
fic.com/products/hausser
_bright_line.html 
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pipette w ml of media and add xy ml of suspension 
pipette into wells, (1 or 2 mls, depending on growth media decided on 
per well).  
 Swirl in North-south-east-west manner and incubate.  
 
Protocol 3: Making up Doxorubicin (dox) treatment 
 Dox molecular weight = 579.98 g/mol, total concentration for 5 day 
treatment = 1µM = 0.2 µM per well per day.  
 If Growth media to be used with drugs per well for a 6 well plate is 
decided as 6ml = 1 ml per well, final volume = 6ml. 
 Dox stock = 3.4mM = initial concentration, final concentration = 0.2µM 
 𝐶1𝑣1 = 𝐶2 𝑣2 
𝑣1 =  
𝐶2𝑣2
𝐶1
 
𝑣1 =
0.2µ𝑀 × 6𝑚𝑙
3.4𝑚𝑀
 
𝑣1 = 0.4µ𝐿 𝑜𝑓 𝑑𝑜𝑥 
You pipette 0.4µL of Dox into 6ml of media.  
 Pipette 1ml into each well.  
Protocol 4: Harvesting cells 
 Get two cooler boxes and fill with ice, work on ice the whole time 
 Add eppis to represent your experimental groups 
 Add the following to 1ml of RIPA solution 
Reagents Volume 
Protease inhibitor cocktail 42µl 
Na3VO4 5 µl 
NaF 5 µl 
*PMSF 10 µl 
 
Table B. 1: RIPA lysis buffer 
*Add PMSF last 
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 Take treated and control plates from incubator, and remove media 
using aspirator.  
 Add 1 ml of PBS to each well, shake and aspirate.  
 Add 50µL of the RIPA solution to each well, working on ice 
 Scrape using scraper and pipette into labelled eppis.  
 Put back in ice,  
 Head on to western blot or freeze away.  
 
Protocol 5: Sample Preparation 
 Sonicate samples with Ultrasonic liquid processor (Misonix) 
 Change amplitude to 10, select manual, select no under “use 
microtip” 
 Put sample eppi in a beaker filled with ice, and place under 
sonicator,  
 Press begin and hold in place for 10 seconds.  
 Press stop, rinse sonicator tip, and dab dry, then go on to next 
sample.  
 Centrifugation 
 Centrifuge at 8000g for 10 minutes.  
Protocol 6: Protein concentration 
 To measure Protein concentration with the Direct detect™ 
spectrophotometer,  
 Shake sample eppis and pipette 2 µl of each sample onto Direct 
Detect ™ Assay-free cards (Merek, DDAC00010-GR) 
 Measure protein concentration using Direct Detect ™ 
spectrometer using the RIPA calibration curve, and RIPA buffer 
as a blank.  
 Read protein concentration values and determine loading 
volumes.  
 Make volumes of protein samples in Laemlli’s sample buffer.  
 Boil at 1000C for 5 minutes 
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 Place in -800C freezer 
 
Protocol 7: Western Blotting 
 Preparation of Gels 
 Prepare well combs, back plates, front plates and clean thoroughly with 
70% alcohol.  
 Set up front and back plates in Western blot Gel holder.  
 Make resolving gel using TGX Stain-Free ™ FastCast ™ (BIO-RAD) kit 
according to manufacturer’s protocol (Appendix B).  
 Briskly fill in plates until green level with Pasteur pipettes 
 Make stacking gel according to BIO-Rad Protocols (Appendix B) 
 Add stacking gel till brim, and place combs in, allow setting for about 
30 minutes.  
 Loading and running samples 
 Remove combs from set gels, place gels in tank and add 1X running 
buffer (appendix B) into middle compartment letting it overflow into tank 
until it levels with the middle compartment.  
 Boil samples for five minutes, load 4 µl BlUeye prestained ladder in the 
first well.  
 Centrifuge boiled samples for 10 seconds, and then load into 
appropriate wells.  
 Place lid onto tank ensuring electrodes are oriented correctly,  
 Connect to voltage box and run at 100 V for 10 minutes then 150 V for 
30 minutes or until running front runs completely through the gel. 
Check that there are bubbles while voltage is running.  
 Gel activation 
 Activate fully run gel on the Chemi-Doc system using the Imagelab 
 Remove gel, place in running buffer, then view on chemi-doc: using 
stain free gel application> gel activation> gels used in blotting.   
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  
Figure B. 2: Stain-free Gel representative image. 
 Transfer 
 Make up 1X RTA transfer buffer (APPENDIX B) 
 Soak top and bottom transfer stacks in transfer buffer.  
 Soak PVDF membrane in methanol 
 Then soak PVDF membrane in transfer buffer for about 3 minutes for 
equilibration. 
 Prepare sandwich (bottom stack, PVDF membrane, Gel, and then top 
stack)  
 Roll out bubbles on each layer to ensure complete contact.   
 Membrane activation 
 Place membrane in ethanol 
 Activate PVDF membrane post transfer using the Chemi-Doc, and 
image-line software. Blots>stain free blot 
  
Figure B. 3: Stain-free blot representative image. 
 Blocking 
 Block the membrane using 5% milk,  
 5ml of milk in 95 ml of TBS tween for an hour on the shaker 
 Antibody binding 
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 Primary Incubation 
 Wash three times for five minute intervals in TBS-tween, then 
place in primary antibody 
 USP 30 and 36 (1-200 in 5% milk) 
 USP 9x (1-1000) 
 MFN 1 (1-10000) 
 MFN 2 (1-1000) 
 Mcl-1 (1-100 in 5% milk) 
 MnSOD (1-1000) 
 TOMM20 (1-1000 in 5% milk) 
 Incubate overnight or for two days at 4o C.  
 Secondary Incubation 
 Wash in TBS-tween three times for at least five minutes intervals 
 Incubate in secondary antibody for at least an hour at room 
temperature 
 USP 30 and 36 (Donkey anti-goat, 1-30000) 
 USP 9x (Anti-rabbit, 1-10000) 
 MFN 1 and 2 (Anti-rabbit, 1-2000) 
 Mcl-1 (Anti-rabbit, 1-10000) 
 MnSOD (Anti-rabbit, 1-10000) 
 TOMM20 (Anti-rabbit, 1-10000) 
 visualization 
 Make up ECL (appendix B), and add about 200 µl to membrane.  
 Visualize on chemi-doc, image-line software 
 Analyze bands  
 
Protocol 8: Immunocytochemistry 
Materials needed 
 Opti-MEM or DMEM supplemented with 10% fetal calf serum (or any other 
media that cells require for growth) at 37oC.  
 Opti-MEM or DMEM without serum at 37oC.  
 Sterile microscope cover slips  
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 Phosphate-buffered saline (PBS) - 1.37mM, NaCl-0.03mM, KCl-0.07mM, 
Ma2HPO4-0.11mM K2HPO4 pH 7.4 store at room temperature.  
 Paraphormaldehyde fixing solution 4% paraphormaldehyde (v/v) in PBS; 
Dilution from paraphormaldehyde solution 37% wt. store at room temperature.  
 Permeabilization solution: Triton X-100 0.2% (v/v) in PBS. Store at room 
temperature 
 Blocking solution: 3% BSA (w/v) in PBS, prepare fresh and maintain at -20oC 
until use. (Donkey serum can be used as well)   
 Primary antibodies:  
 Fluorescent Secondary antibodies:  
 Hoechst stain 
 Mounting media: DAKO fluorescent mounting media (DAKO cytomation, S 
3023) 
 Dark wet Chamber (aluminium lined box with yellow cap).  
Methods 
 Cells grown on sterile cover slips at the bottom of 12-well plates (1 mL growth 
medium) until semi-confluent (50-70% confluence: e.g. NT2 Rho0, Cybs – 
plating an appropriate amount of cells/ml) are washed twice with serum-free 
culture medium at 37oC (to remove all remaining IgG in the serum) and once 
with serum-free culture medium paraphormaldehyde fixing solution (1:1) FOR 
10 MIN (500 µL culture medium plus 500 µL 4% paraphormaldehyde fixing 
solution).  
 Then cells are fixed in paraphormaldehyde fixing solution for 10 minutes at 37 
degrees. Cells can be washed twice with PBS then stored in PBS containing 
0.02% NaN at 4 degrees in the dark for weeks. 
 To start the immunofluorescence procedure, PBS is aspirate sand slides are 
placed facing up in a 12 multi-well cap layered with parafilm.  
  Then 100µL of permeabilization solution are added per well. Permeabilization 
is completed by incubating the slides for 2 minutes at room temperature.  
 After aspiration, 100µL of blocking solution are added per well. Blocking is 
completed by incubating the slides for 30 minutes at room temperature and 
washing the slides three times with PBS.  
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 The primary antibodies are diluted in 3% BSA in PBS then 100µL of diluted 
primary antibody is spotted on top of each slide. Incubation with the antibody 
is carried out in a wet chamber overnight in the cold room (additionally paper 
soaked in water is placed inside the chamber to prevent drying of the antibody 
solution).  
 Slides are the extensively washed with PBS by spotting on and aspirating the 
slides sequentially with 100µL PBS each time.  
 After aspirating the excess of PBS in the slides, they are incubated with 
100µL of the secondary antibodies for 1hr at room temperature in a dark wet 
chamber. Better results are obtained if the dilutions of these secondary 
antibodies are spun down before adding to the slides to remove any possible 
aggregated flourochorme.  
 Add a 1-200 dilution of Hoechst stain over the secondary antibody for 10 
minutes. 
 After washes and removal of the excess PBS, slides are mounted by placing 
them face down on top of 10µL of DAKO-mounting media spotted on a 
previously cleaned glass slide and sealed with nail polish to prevent drying.  
 The slides are then stored in a dark box at room temperature until 
visualization in the fluorescence microscope.  
Protocol 9: Transfection/Knock down (Invitrogen electroporation device) 
Kit includes 
 Neon™ electroporation device 
 Neon™ pipette station 
 Neon™ electroporation pipette 
 Neon™ pipette tips 
 Neon™ tube 
 Electrolytic buffer  
 Resuspension buffer 
Materials supplied by user 
 Appropriate plate for seeding 
 Microcentrifuge eppis 
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 Plasmid/siRNA 
Procedure 
 Grow up cells in sterile conditions. 
 Trypsinize, count and resuspend cells once enough cells have been grown.  
 Resuspend cells in resuspension buffer “R” provided by Invitrogen at 
appropriate seeding density optimized for cell type. 
 Add optimized SiRNA/DNA amount to resuspended cells and mix.  
 Insert the Neon™ tube into the Neon™ station until a click is heard, and fill 
with 3 ml electrolytic buffer. 
 Using the Neon™ pipette, pipette 10 µl/100 µl of the cell-siRNA/DNA mix 
(depending on tip size used), avoiding bubbles. 
 Insert the pipette into the tube until a click is heard, and then initialize pre-
determined protocol on the Neon™ device.  
 Seed the electroporated cells into wells containing media in appropriate 
plates. 
 Place in incubator and check for transfection efficacy after 24 hrs.    
Protocol 10: Mitochondrial morphology (live cell imaging) 
Materials needed 
 Nunc™ Lab-Tek™ 8-well chamber plates 
 Olympus IX81 fluorescent microscope  
 Mitotracker green stock solution (prepared in DMSO at 5 mM) 
Method 
 Cells were cultured in 8-well chamber slides.  
 Mitotracker green was added to the slides in media at a concentration of 0.5 
µM and incubated for 20 minutes at room temperature.  
 Hoechst was also added at a 1-200 dilution for an extra 10 minutes at room 
temperature.  
 Cells were visualized with the Olympus fluorescent microscope at 60X 
magnification and Z-stack images were acquired.  
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Protocol 11: Mitochondrial ToxGlo™ Assay (Promega) 
Kit components (10 ml Kit, G8000) 
 10 ml Assay Buffer 
 10 µl bis-AAF-R110 substrate 
 10 ml ATP detection buffer 
 1 vial ATP detection substrate 
Components provided by user 
 Digitonin/Saponin 
 96-well plate 
 Orbital shaker 
 Luminometer 
 Fluorescence plate reader 
 Growth medium 
*Storage: This kit is stored at -20 oC 
Reagent preparation 
 Cytotoxicity reagent preparation 
o Thaw the assay buffer and bis-AAF-R110 substrate in a 37 oC 
water/bead bath 
o Transfer 2 ml of the assay buffer into a clean tube and add 10 µl bis-
AAF-R110 for a 5X cytotoxicity reagent.  
o Mix by vortexing until substrate is well dissolved and use within 24 hrs.  
 ATP detection reagent preparation 
o Thaw ATP detection buffer at 37 oC.  
o Transfer 10 ml of ATP detection buffer to the bottle containing the ATP 
detection substrate for a 2X ATP detection reagent.  
o Mix by vortexing and equilibrate to room temperature.  
o Use within 24 hrs 
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Procedure 
 Grow sufficient cells in sterile conditions.  
 Trypsinize and resuspend cells at 200 000 cells/ml 
 Plate 50 µl of cell suspension into appropriate wells in a 96-well plate.  
 Allow cells to adhere.  
 Prepare cytotoxicity and ATP detection reagents. 
 Add 20 µl of the 5x cytotoxicity reagent into the wells, mix briefly by orbital 
shaking, and incubate at 37 oC for 30 minutes. 
 Measure fluorescence at 485 nmEX/520-530EM.  
  Equilibrate to room temperature for 5-10 minutes.  
 Add 100 µl of the ATP detection reagent to each well and mix by orbital 
shaking for 1-5 minutes.  
 Measure luminescence.  
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Appendix C 
 
Reagent Preparation 
Protocol 1: Growth Medium  
Materials needed:  
 500 mL DMEM 
 50 mL FBS (10%) 
 5 mL Penicillin Streptomycin (PenStrep) 
Preparation 
 Thaw all components in the 37 oC bead bath.  
 Under sterile working conditions, pipette 55 mL of DMEM from the stock bottle 
 Add 50 mL filtered FBS and PenStrep and invert gently to mix.  
 Aliquot into 50 ml falcon tubes and store at 4 oC.  
Protocol 2: Doxorubicin stock 
Materials needed:  
 Doxorubicin Hydrochloride (Mg = 579.98 g/mol) at 3.4 mM 
 Culture medium (DMEM) 
Preparation  
 Under sterile conditions, dissolve 10 mg Doxorubicin in 5.071 mL of medium 
 Vortex, filter-sterilize and store in aliquots in the dark at -20 oC.  
 
Protocol 3: Transfection Medium 
Materials needed:  
 50 mL DMEM 
 5 mL FBS 
Preparation 
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 In sterile working conditions, dissolve 5 mL of FBS in 50 mL DMEM.  
 Invert and store at 4 oC.  
Protocol 4: Phosphate Buffer Saline (PBS) 
Materials needed:  
 16 g NaCl 
 0.4 g KCL 
 2.88 g Na2HPO4 
 0.48 g  
Preparation: 
 Dissolve all components in 1 L of distilled water 
 Adjust to 7.4 pH 
 Fill up to 2 L with distilled water 
 Autoclave 
Protocol 5: 95% alcohol 
 Dilute 950 mL of 100% ethanol in 50 mL distilled water 
Protocol 6: 70% alcohol 
 Dilute 700 mL 100% ethanol in 300 mL distilled water 
Protocol 7: RIPA Buffer 
 Prepare 50 mM Tris-HCL:  
o Add 700 mg Tris to 75 mL distilled water.  
o Add 900 mg NaCl and stir then adjust pH to 7.4.  
o Aliquot and store at 4 oC 
Protocol 8: RIPA working solution 
 To 1 ml of RIPA buffer, add 42 µL of Protease inhibitor cocktail, 5 µL NaF, 5 
µL Na3VO4 and 10 µL Phenylmethylsulponyl Fluoride (PMSF) 
Protocol 9: Bovine serum Albumin (BSA) 
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 To prepare a 2 mg/mL stock of BSA, weigh off 20 mg and mix thoroughly in 
10 mL of distilled water.  
 Freeze in aliquots of 1 mL 
Protocol 10: Laemmli’s Sample Buffer (Stock) 
 3.8 mL distilled water 
 1 ML 0.5M Tris-HCL, pH 6.8 
 0.8 mL glycerol 
 1.6 mL 10% (w/v) SDS 
 0.4 – 1.0 mL 0.05% (w/v) Bromophenol blue 
For western Blotting, make a working solution by adding 150 µL β-mercaptoethanol 
to 850 µL Laemmli’s stock Solution.  
Protocol 11: 10% Sodium dodecyl sulphate (SDS) 
 Weigh out 50 g SDS and add 500 mL distilled water 
Protocol 12: 10X running buffer  
 A 5 L 10X running buffer pack was purchased from Bio-RAD (1610772) 
 Buffer make up includes (25 mM Tris, 192 mM glycine, 0.1% SDS).  
 Dilution to 1X stabilizes pH at 8.3.   
 Dilution to 1X (100 mL of 10X running buffer made up to 1 L with dH2O) 
Protocol 13: Transfer buffer (Bio-Rad, 1704272) 
 To make up 1 L transfer buffer, dilute 200 mL  5X BIO-RAD Transblot ® Turbo 
™ RTA transfer buffer in 200 mL 100% alcohol, and 600 mL dH2O. 
Protocol 14: 10X TBS 
 Dissolve 24.2 g Tris and 80 g NaCl in 600 mL distilled water 
 Adjust pH to 7.6 with HCL 
 Fill up to 1L with distilled water 
 To make up TBS tween, mix 100 mL 10X TBS in 900 mL distilled water with 1 
mL Tween 20.  
Protocol 15: 10% Ammonium Persulphate (APS) 
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 Dissolve 0.5 g APS in 5 mL distilled water.  
Protocol 16: Tris pH 8.8 
 Dissolve 6.057 g Tris (100 mM) in 400 mL distilled water, mix and adjust pH to 
6.7 using HCL.  
 Make up final volume to 500 mL with distilled water 
Protocol 17:  BIO-RAD TGX Stain-free ™ Fastcast ™ Gels. 
 To make one 1.00 mm mini Gel using the Bio-Rad 12% stain-free fastcast ™ 
acrylamide kit;  
 1.0 mm Bio-Rad Glass plates (n = gels) 
Stacker Resolver 
Resolver A - 3 ml * n 
Resolver B - 3 ml * n 
Stacker A 1 ml * n - 
Stacker B 1 ml * n - 
Total Volume 2 ml * n 6 ml * n 
TEMED 2 µl * n 3 µl * n 
10% APS 10 µl * n 30 µl * n 
 
Table C. 1: Bio-Rad Stain-free Fast-cast gel preparation. 
 Stir and dispense the resolving gel first, then the stacking gel, and then insert 
well combs and allow setting for ± 45 minutes.  
Note: add 75 µL TCE to resolving solution if the fast cast gels are not stain-free 
Protocol 18: Milk blocking solution  
 Weigh out 5 g fat-free instant milk powder and dissolve in 100 ml TBS-tween.  
 Alternatively, dissolve 5 ml Fat free milk in 95 ml TBS-tween.  
Protocol 19: Primary (1o) and secondary (2o) Antibody 
 Pipette appropriate antibody volume according to recommended or optimized 
dilution ratios into 5 mL TBS-tween.  
Protocol 20: Clarity ™ Western ECL Substrate, 200 ml (Bio-Rad, 1705060) 
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 Mix equal volumes of white and black clarity substrates preferably in the dark.  
Protocol 21: Stripping Buffer 
 7.5 g glycine 
 0.5 g SDS 
 5 mL Tween 
 Dissolve in ± 300 mL distilled water 
 Adjust pH to 2.2 
 Fill up to the 500 mL with distilled water.  
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Appendix D 
Ethics Approval Letter 
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